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Abstract
Few studies have investigated methadone maintenance treatment of opiate
dependent patients in primary health care settings compared to specialist clinic
settings. Using a prospective cohort design, the study investigated outcomes at one
year for 660 patients treated by general practitioners (n = 70) or by drug clinics (n =
3) at sites across Basel, Switzerland. The main treatment outcome measures were:
retention in treatment, attendance of consultations, prescribed methadone doses,
and illicit drug use over time. Mean daily methadone dose for patients in general
practice (GP) was 69.3 mg (SD = 44.7) and for patients in specialized clinics 76.7 mg
(SD = 48.4). The overall one-year retention in treatment  was 74% (GP, 75.6%;
clinics, 72.2%). The proportion of reported concomitant heroin use was significantly
lower in patients treated by GPs compared to the clinic sample (49% versus 72%; P
< 0.0001), as well as the proportion of reported concomitant cocaine use (GP, 24%;
clinics, 41%; P = 0.001). The same accounts for reported intravenous drug use (GP,
40% versus 58%; P < 0.0001). The concomitant use of benzodiazepines and alcohol
did not differ between groups. Reductions in concomitant heroin and cocaine use
were found in both groups at follow-up, by comparing admission, with average-stay
and long-term samples. Patients in GP settings attended an average of 5.14 out of
6.19 scheduled consultations, patients in specialist clinic settings an average of 6.8
out of 7.86 scheduled consultations in a six-month period. The proportion of take-
home medication for both groups was 69%. Comparing treatment outcome with the
amount of consultations in both treatment settings, patients with a higher rate of
consultations (4 to 7) had a significantly better retention rate in both groups (P =
0.002; P< 0.0001) compared to patients with a low rate of consultations (0 to 3).
Results show substantial reductions in concomitant heroin use, among ‘real world’
patients treated in GP and in clinic settings, which were sustained at one-year follow-
up. Our results support the success of methadone maintenance provided by primary
care physicians’ offices. Furthermore, our results provide evidence, that GPs treat an
equal proportion of ‘unstable patients’ (25%) as do the clinics, indicating the
knowledge and long clinical experience of this sample of GPs. However, providing
better professional support, competence training and financial remains a goal for
future developments in the primary health care field.
11. Introduction
Methadone prescribing to opioid-dependent individuals has become much more
available over the past decade, both in countries with a history of its use like the UK,
Australia, the Netherlands, Spain, Italy and Switzerland, and in countries round the
world which previously had no methadone prescribing like France and Germany. In
some of these countries (the UK, the Netherlands, Spain, Italy and Switzerland)
methadone maintenance treatments (MMT) are provided by primary care and
specialized clinics. In the United States the current narcotic treatment system is able
to provide the most effective medical treatment for opioid dependence to only
170'000 of the estimated 810'000 oipoid-dependent individuals (National Consensus
Development Panel, 1998). This lack of adequate treatments persists despite the
demonstrated effectiveness of methadone maintenance in decreasing the medical,
legal, and infections complications associated with heroin use (Ball & Ross, 1991;
Metzger et al., 1991; Cooper et al., 1989). Critical statements against MMT argue,
that the problem of methadone diversion is not solved. Methadone treatment has
been researched for three decades and it has been reported that, when correctly
implemented, this treatment can provide benefits for opioid dependent patients and
the community and lower the mortality rate associated with opioid use (Caplehorn et
al., 1994; Goldstein et al., 1973; Gunne et al., 1981; Kreek et al., 1981; Ball & Ross,
1991; Dole et al., 1969).
1.1 Opioid Abuse and Dependence
Before summarizing the research conducted in methadone maintenance treatment
we will give a short overview of the APA Classification (American Psychiatric
Association, 1994; DSM IV) and the WHO classification (WHO, International
Classification of the World Health Organization, ICD-10, 1991) of opioid abuse and
dependence. As we can see in the following section (substance dependence, criteria
6), the APA Classification outlines more the “important social, occupational (...)
activities” that “are  given up or reduced” (APA, 1994) than the WHO-Classification.
APA Classification: the Diagnostic and Statistical Manual – DSM-IV
Opioid Abuse and Dependence:
A. Characteristics and Major Features
1. Opioid dependence is a state characterized by behavioral and physiologic
symptoms that result in continued use of opioid substances despite harm.
2. Hallmarks include prolonged self-administration of opioid substances despite
significant adverse effects, often accompanied by tolerance and/or withdrawal.
3. Physiologic manifestations result from changes in brain receptor function and
neurochemical signaling induced by chronic exposure to opioid agonist
substances such as heroin.
4. Psychological and behavioral manifestations of opioid dependence are major
causes of dysfunction and morbidity.
2B. Criteria for Substance Abuse and Substance Dependence (DSM-IV)
1. SUBSTANCE ABUSE (American Psychiatric Association, 1994)
A. A maladaptive pattern of substance use leading to clinically significant
impairments or distress, as manifested by 1 (or more) of the following occurring
within a 12-month period:
1. recurrent substance use resulting in a failure to fulfill major role obligations at
work, school or home
2. recurrent substance use in situations in which it is physically hazardous (e.g.,
driving an automobile or operating a machine when impaired by substance use)
3. recurrent substance-related legal problems
2. SUBSTANCE DEPENDENCE (American Psychiatric Association, 1994)
A. A maladaptive pattern of substance use leading to clinically significant
impairments or distress, as manifested by 3 (or more) of the following occurring at
any time in the same 12-month period:
1. Tolerance, as defined by either of the following:
a. a need for markedly increased amounts of the substance to achieve intoxication
or desired effect
b. markedly diminished effect with continued use of the same amount of the
substance
2. Withdrawal, as manifested by either of the following:
a. the characteristic withdrawal syndrome for the substance
b. the same (or closely related) substance is taken to relieve
3. The substance is often taken in larger amounts or a longer period than was
intended.
4. There is persistent desire or unsuccessful effort to cut down or control substance
use.
5. A great deal of time is spent in activities necessary to obtain the substance (e.g.,
visiting multiple physicians), use the substance (e.g., chain-smoking), or recover
from its effects.
6. Important social, occupational, or recreational activities are given up or reduced
because of substance use.
7. The substance use is continued despite knowledge of having a persistent or
recurrent physical or psychological problem that is likely to have been caused or
exacerbated by the substance.
The International Classification of the World Health Organization (ICD-10)
International Classification of Diseases (ICD-10, 1991):
The ICD-10 criteria of opioid dependence (F1) are very similar to the DSM-IV criteria.
Three or more of the following must have been experienced or exhibited at some
time during the previous year:
1. Difficulties in controlling substance-taking behavior in terms of its onset,
termination, or levels of use
2. A strong desire or sense of compulsion to take the substance
3. Progressive neglect of alternative pleasures or interests because of psychoactive
substance use, increased amount of time necessary to obtain or take the
substance or to recover from its effects
34. Persisting with substance use despite clear evidence of overtly harmful
consequences, depressive mood states consequent to heavy use, or drug related
impairment of cognitive functioning
5. Evidence of tolerance, such that increased doses of the psychoactive substance
are required in order to achieve effects originally produced by lower doses
6. A physiological withdrawal state when substance use has ceased or been
reduced, as evidence by: the characteristic withdrawal syndrome for the
substance; or use of the same (or a closely related) substance with the intention
of relieving or avoiding withdrawal symptoms
1.2 Epidemiology of Opioid Dependence
Heroin abuse and dependence are serious health problems with profound effects on
individuals and society. Costs to society are estimated at $20 billion per year with
$1.2 billion per year of direct health care costs in the U.S. (Fiellin et al., 2002). There
are an estimated of 2.4 million Americans who reported using heroin at some time in
their lives, thus the lifetime prevalence of people age 12 or older was 1.4 percent
(National Household Survey on Drug Abuse, 1997). During 1991 – 1995 opioid-
related deaths increased from 2300 to 4000 (Drug Abuse Warning Network, 1999).
Most of the new heroin users are under the age of 25. Evidence suggests that heroin
snorting and smoking has become common in those areas of the United States in
which high-purity heroin is readily available. This accounts also for the European
Countries. Authors from the “Monitoring the Future Study” (MTF, 1999) analyzed
heroin use by students in 1999. Although year prevalence rates for heroin use
remained  relatively low in 1999, these rates were about two to three times higher
than those reported in 1991 and the use began to rise among 10th- and 12th-graders.
The same accounts for cocaine use, the percentage of 8th-graders who had ever
tried cocaine has increased from a low of 2.3 percent in 1991 to 4.7 percent in 1999
(table 1).
Table 1: Heroin Use by Students in the United States, 1999 (N = 49'866)
8th-Graders 10th-Graders 12th-Graders
Ever Used 2.3% 2.3% 2.0%
Used in Past Year 1.4 1.4 1.1
Used in Past Month 0.6 0.7 0.5
Monitoring the Future Study (MTF), 1999, National Institute on Drug Abuse (NIDA)
Recent estimates are that there are approximately 810'000 chronic heroin users in
the U.S. However, only 170'000 of these are currently receiving treatment with the
most effective form of therapy – an opioid agonist therapy such as methadone.
A recently published Swiss survey of 10'115 schoolgirls and schoolboys (aged 11
years to 16 years) reported a prevalence rate of 0.5% for heroin use and 3.4% for
cocaine use (Schweizerische Fachstelle für Alkohol u. Drogenfragen, 2003). Heroin
use remained unchanged in the past 10 years, whereas cocaine use increased
significantly from 1.7% to 3.4% prevalence. This is similar to the American results
from the MTF-study.
In Switzerland, there are an estimated of 1.3% of the total population who reported
using heroin at some time in their lives, with a sex ratio of 3 to 1 for men
(Schweizerische Fachstelle für Alkohol u. Drogenfragen, 1995). There are an
estimated of 30'000 persons having an opioid dependence (Esterman, 1996). 3% of
the persons aged 15-39 years have tried heroin or cocaine at least one time in their
life. For drugs like cannabis an estimated of 600'000 persons aged 15-39 years have
tried cannabis at least one time in their life. In Switzerland, the number of heroin
addicts has remained stable since 1990, and  deaths from overdose have decreased
from 419 in 1992 to 197 persons in 2001 (Bundesamt für Gesundheit, SPECTRA,
2002, Fig. 1). The category in the Federal statistic is not clearly defined and must be
well understood: most persons died from multiple drug use, but there also suicide,
accidents on the road or at work and persons dying from AIDS disease (Fig. 1).
Nevertheless, there has been a considerable decrease drug-related deaths (ODs)
since 1992 in Switzerland and in Basel (Fig. 1). This is due to the considerable efforts
of the Swiss public health authorities and the experts in addiction medicine by
expanding the drug treatment system in the last 25 years in Switzerland. In particular
there has been a growth of the non-residential sector and the low-threshold
programs, including methadone maintenance treatment, the establishing of injection
rooms and controlled heroin prescription in specialized clinics (Klingemann, 1996).
Figure 1: Number of Persons Died from an Overdose (OD) Over Time, in
Switzerland and in Basel
O
P
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Ds in Switzerland: Adapted from, Bundesamt für Gesundheit, Statistik des Bundesamtes für
olizeiwesen BAP, polizeilich registrierte Fälle (2002).
Ds in the City of Basel: Adapted from, Statistisches Jahrbuch des Kantons Basel-Stadt (2001).
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51.3 Pharmacology of Opioids
The most important pharmacological actions of the opioids are euphoria and
analgesia; “they alter the response to the perception of pain in doses which have
comparatively minor effects on other functions of the central nervous system “ (NIDA,
1986). There are three major types of opioid receptors: the M receptor (mediates
euphoria, analgesia, and sedation); the Kappa receptor (mediates dysphoria,
analgesia); and the Delta receptor (Goldstein, 1991).  Endogenous peptides which
bind to these receptors are enkephalins, endorphins. M receptors have a high
affinity to opioids, enkephalins and beta-endorphins. Opioids mimic the action of the
endogenous neurotransmitters in the brain by utilizing and activating the same
receptor sites (Brown, 1976; Swan, 1997). Repeated (chronic) exposure to short-
acting opioids (e.g., heroin) leads to neuronal adaptations resulting in tolerance,
dependence, and craving. Replacement therapies with methadone aimed at
stabilizing these neuronal circuits (Nestler & Aghajanian, 1997).
Different pharmacotherapies have been researched and developed in the last three
decades for the treatment of opioid dependence. Full agonists (e.g. methadone)
binds and activates the receptor, partial agonists (buprenorphine) binds and partially
activates the receptor, antagonists (naloxone) binds but does not activate the
receptor (table 2). M, delta and kappa opioid receptors belong to a family of
receptors know as the G-protein-coupled receptors – found on the cell surface. When
these bind to drug (heroin), G-proteins activated within cell produce drug-inducted
euphoria. Other effects include: analgesia, respiratory depression, constipation and
miosis (Ling & Wesson, 1990; Kleber, 1994). Extended use of opioids that binds to
the m receptor is associated with physical dependence and withdrawal syndrome
when they are removed (Ling & Wesson, 1990). Natural opioids and their synthetic
analogs are cross-tolerant and cross-dependent (Akers, 1992; table 2).
Table 2: Opioid Agonists and Antagonists
Agonists
(naturally
occuring)
Semi-synthetic
Agonists
Synthetic Agonists Partial Agonist and
Mixed
Agonist/Antagonist
Antagonists
Opium Heroin
(Diacethylmorphine)
Methadone
(dl-6-Dimethylamino-
4,4diphenyl-3-
heptanon)
Buprenorphine
(Subutex)
Naloxone
(Narcan)
Paregoric Hydromorphone LAAM Pentazocine Naltrexone
(Nemexin)
Morphine Oxycodone Propoxyphene Nalorphone Nalmefene
Codeine
(Methylmorphine)
Hydrocodone Fentanyl Nalbuphine
Akers, 1992
1.4 Opioid Abuse and Psychopathology
Psychiatric comorbidity in opioid dependence is common (Cacciola et al., 2001;
Moggi, 2002). The following disorders are seen in association with opioid
dependence in daily clinical practice: Abuse or dependence on another substance
including tabacco, alcohol, cocaine or benzodiazepines; depression; anxiety
disorders; antisocial personality disorder; and other personality disorders.
61.4.1 Abuse or Dependence on Another Substance or on Multiple Substances
Gossop and colleagues (1999, 2001, 2003) analyzed in a National Treatment
Outcome Research Study  (NTORS) in the UK the pretreatment diagnosis of 1075
patients before entering a methadone maintenance program and found, that multiple
substance use before treatment is nowadays the norm (Gossop et al., 1999, 2001,
2003). 11% reported use of heroin and cocaine before treatment, 24% heroin,
cocaine, and benzodiazepine use, 30% heroin, cocaine, benzodiazepine and alcohol
use. Almost 98% percent used tobacco. Thus, most patients used beside heroin
three additional substances. Nevertheless, most clinicians do not use the term
“multiple dependences”, but define for each substance a separate diagnosis, as it is
defined in the DSM-IV and the ICD-10. The NTORS study also showed, that 50% of
the patients dying from a so called “overdose” had 4 or more substances in their
bodies and were heavy drinking subjects (autopsy reports).
1.4.2 Depression
Lifetime prevalence of depression in methadone maintained patients is estimated
between 16-54% (Rounsaville et al., 1982; Brooner et al., 1997; table 3).  Depression
may have preceded the onset of drug abuse and a major depressive episode may
develop in the context of opioid addiction. It occurs more commonly in women than in
men. Treatment with antidepressants and psychotherapy is indicated and frequently
helpful if the individual is abstinent from illicit drug use.
1.4.3 Anxiety Disorders
Panic disorder, obsessive-compulsive disorder, generalized anxiety disorder and
phobia are seen in approximately 10% to 30% of opioid dependent persons
(Khantzian et al., 1985; Regier et al., 1990; Cacciola et al., 2001; table 3). This group
of persons is somewhat younger in age and higher in socioeconomic status and their
drug use histories are not as extensive (Fiellin et al., 2002). Cacciola and colleagues
(2001), found at methadone maintenance treatment entry 8% of the patients with
panic disorder, 11% with a social phobia, 21% with a simple phobia and 33% with a
post traumatic stress disorder (PTSD) (table 3). The high rate of PTSD is probably
due to the high incidence of physical and sexual abuse among many opioid
dependent patients (lifetime and current).
1.4.4 Personality Disorders
Antisocial personality disorders are the most commonly diagnosed with a prevalence
rate between 25-35% (table 3). The majority are men. The second most diagnosed
personality disorder is the borderline personality disorder with a prevalence rate of
10%, with no gender differences. “Personality disorders can be diagnosed historically
in most individuals at a young age prior to onset of opioid dependence” (Fiellin et al.,
2002, p. 11). The Epidemiologic Catchment Area (ECA) study (Regier et al., 1990)
was a large-scale survey of the prevalence of psychiatric disorders conducted in the
USA. The ECA findings are of interest, because the allow a comparison of lifetime
rates in the general population with opioid users. Opioid users were found to be
7seven times more likely to have experienced a psychiatric disorder than the general
population (table 3).
In a Swiss study, Kuntze and colleagues (1998) found in 126 methadone maintained
patients 70.7% with two or more diagnoses of substance related disorders.
Personality disorders were found in 45% of the patients, depressive disorders in
25%, schizophrenic disorders in 14% and anxiety disorders in 5%.
Table 3: Estimates of Prevalence of Psychiatric Comorbidity in the Opioid
Dependent and in the General Population
Author Sample
Type (N)
Prevalence
rate
(currenta or
lifetimeb)
Any
psychiatric
diagnosis
%
Depressive
disorder
%
Anxiety
disorder
%
Alcohol
use
disorder
%
Antisocial
personality
disorder
%
Rounsaville
et al.
(1982)
Opioid
dependentc
533
Current 70 26 3 14 27
Khantzian
& Treece
(1985)
Opioid
dependentc
133
Current 93 56 11 14 35
Woody et
al. (1983;
1985)
Methadone
patients 110
Lifetime - 43 7 26 15
Strain et al.
(1991)
Methadone
patients
66
Lifetime 47 23 2 49 30
Regier et
al. (1990)
Opioid users
142
Lifetime 65 31 32 66 37
Brooner et
al. (1997)
Methadone
patients
716
Current 47 16 - - 25
Cacciola et
al. (2001)
Methadone
patients
278
Current 75 35 24 14 28
Regier et
al. (1990)
General
Population
sample
20'291
Current
Lifetime
‘Relative
risk’d
13.0
22.5
6.7
5.2
8.3
5.0
7.3
14.6
2.8/
2.8
13.5
12.8/
0.5
2.6
24.3
Adapted from Ward et al., 1992, p. 259.
Notes. a ’Current indicates that the individual currently has the disorder; b ‘Lifetime’ indicates that the
individual has had disorder at some time in life. c Refers to a mixed sample of opioid-dependent
individuals, some of whom were in treatment some were not in treatment. d  The figures on ‘relative
risk’ are odds ratios reported by Regier et al. (1990) and indicate the increased likelihood that a person
meeting diagnostic criteria for opiate abuse or dependence will also meet criteria for the diagnoses
indicated.
1.5 The Early Methadone Maintenance Treatment Programs
In the early 1960s, Dole and Nyswander introduced orally administered maintenance
doses of the synthetic opioid drug methadone as a drug-substitution treatment for
opioid dependence. Methadone is a full agonist acting at the m receptors and
replacing the shorter-acting heroin that is usually injected (Dole and Nyswander,
81965). Methadone is taken orally once a day because its long duration eliminates
opiate withdrawal symptoms for 24-36 h, decreases craving for heroin and blocks its
euphoric effects (table 4).
Table 4: Methadone versus Heroin
Methadone Heroin
Route Oral Intravenous,
Intranasal
Onset 30 minutes Immediate
Duration 24-36 hours 3-6 hours
Euphoria Absent Marked
Adapted from Dole & Nyswander, 1965
According to Dole and Nyswander, opioid dependence was perceived as “a
physiological disease characterized by a permanent metabolic deficiency” (1965, p.
84). Thus, this deficiency was treated by administering to the opioid-dependent
patient a sufficient methadone dose as a substitute to stabilize the metabolic
deficiency. This allowed the patients to “improve his social functioning by taking
advantage of the psychotherapeutic and rehabilitative services” that were an integral
part of these early methadone maintenance programs (Dole & Nyswander, 1967, p.
22).
The early MMT were based on the following model of treatment process: entering
treatment, induction phase, maintenance phase, detoxification phase, after care. This
model of addiction treatment is derived from the early abstinence oriented therapeutic
communities (1965, Daytop, Synanon, Phoenix) which comprised: detoxification,
entering therapy, therapeutic phase with behavioral-emotional change, visiting after
care services or self-help groups to maintain abstinence after the therapy. This 4-step
model of addiction treatment was introduced in Europe first in the therapeutic
communities (Petzold, 1974), and then later in non abstinence oriented treatments
like MMT (Petzold et al., 2000). Nowadays, many clinicians, psychotherapists and
experts in addiction medicine in the U.S. consider that for many patients the main
objective of a MMT is abstinence from all non prescribed substances, and not a total
abstinence from any substances.
In the early American MMT the inclusion criteria for a treatment with methadone
were: a heroin dependence of at least 4 years, the patient had failed in at least two
residential treatments, they were aged 21 or older, and had no alcohol or polydrug
use. In the induction phase patients were hospitalized for six weeks to find the
individual adequate methadone dose. In the maintenance phase takehome
methadone medication were allowed after a stable phase without concomitant heroin
use. Urinalysis were performed three times a week. In 1972 the U.S. indication
criteria for MMT were revised and less stringent to allow more opioid-dependent
persons to have access to these treatments. The actual criteria are: a heroin abuse
of 1 year with a physical dependence, aged 18, an initial maximal methadone dose of
of 30 mg (the maximum maintenance dose is 120 mg), clinical, medical examination
before starting MMT, urinalysis and regular 6-month follow-up interviews. Takehome
medications are only allowed for stable patients, without concomitant heroin use, and
is only allowed for methadone doses below 100 mg. After the maintenance phase the
patient has the possibility to stop the treatment and the methadone dose is gradually
decreased until 0 mg. Post-treatment aftercare services are very important due to the
high proportion of 82 percent of the patients relapsing to heroin use after one year
post-treatment phase (Ball & Ross, 1991).
91.6 The Effectiveness of Methadone Maintenance Treatment
Methadone treatment has been researched for three decades. The most important
active ingredient of MMT has been debated in the research community, asking,
whether it is simply the provision in a controlled manner of a strong opioid or whether
the counseling and the program structure are the most important factors promoting
change (Strain et al., 1993).
1.6.1 Randomized Controlled Trials of Treatment Effectiveness
Carrying out rigorous research in the field of addiction is difficult. As a result
controlled studies are rare. Only five randomized controlled trials have ever taken
place in the 35 years since MMT was introduced (Ward et al., 1992; table 5). All five
trials involved small numbers of patients who were rarely followed for longer than one
year (Dole et al., 1969; Gunne et al., 1981). Dole and colleagues compared
methadone maintenance in New York City in 1969 with a no treatment control and
found at 12 month follow up that subjects in the control group were 92 times more
likely to be using heroin daily than were those in the methadone group, and they
were 53 times more likely to have been incarcerated. The other two RCTs were
double blind, placebo controlled studies that compared methadone and a placebo,
with support services available to all patients (Newman et al., 1979; Strain et al.,
1993; table 5).
Table 5: Randomized Controlled Trials
No. Of
groups
Maintenance
duration
Number
of
subjects
Type of
subjects
Design Results Reference
2 12 months
and
12 months
post-release
32 Opioid-
dependent
Randomized
Controlled Trial
Controls were 92 times
more likely to use heroin
daily, and 52 times
more likely  to be
reincarcerated.
Dole et al. [1969]
New York
2 24 months 36 Opioid-
dependent
Randomized
Controlled Trial,
sequential
design
Controls were 38 times
more likely to use heroin
daily, and had
a significant higher
mortality rate.
Gunne et al.
[1981]
Sweden
2 32 weeks,
3-year
follow-up
100 Opioid-
dependent
Randomized
Double-blind
placebo
controlled
Treatment retention:
control: 10%
methadone: 76%
Newman et al.
[1979]
Hong Kong
2 45-day 240 Opioid-
dependent
Randomized
Controlled Trial
Treatment retention:
control: 34%
methadone: 76%
heroin-positive urines:
control: 53%
methadone: 28%
Vanichseni et al.
[1991]
Bangkok
2 12 months 301 Opioid-
dependent
Randomized
Controlled Trial,
waiting list
Heroin-positive urines:
control: 60%
methadone: 29%
Yancovitz et al.
[1991]
New York
All of these trials found, that methadone maintenance was superior to control
conditions on several measures like illicit use of opioids, crime activity, and mortality.
Another randomized study compared methadone maintained patients with patients in
a gradual methadone withdrawal schedule (Vanichseni et al., 1991; table 5), and one
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compared methadone maintenance without support services with controls in a
waiting list (Yancovitz et al., 1991; table 5). Both of the studies found a superiority for
the patients treated with methadone. “Taken together, the randomized studies of
methadone maintenance show consistent positive results over vastly different cultural
contexts (United States, Hong Kong, Sweden, Thailand) and over more than two
decades of research “ (Farrell et al., 1994, p. 309).
1.6.2 Observational Studies of Treatment Effectiveness
The major observational studies have generally supported the results from the RCTs
(Gearing et al., 1974; Hubbard et al., 1989; Simpson & Sells, 1982; Anglin et al.,
1984; Ball & Ross, 1991; table 6). Observational studies of treatment effectiveness
comprise two major types. „First there are comparative studies in which the outcomes
are compared in persons who selected themselves into different treatments (i.e.
methadone maintenance, therapeutic communities, drug-free counseling). Secondly,
there are pre-post evaluations of treatment in which a group of people entering a
single type of treatment are assessed at intake and at some time after treatment,
assessing changes in ‘outcome’.” (Ward et al., 1992, p. 22). According to Ward and
colleagues the major problem with all observational studies is weather the people
receiving different forms of treatment were comparable prior to treatment. The
strategy of quasi-experimentation provides a way of making inferences about
treatment effectiveness.
Observational studies with some degree of control have surveyed large samples of
opioid dependent subjects, enrolled in MMT and have confirmed that methadone
maintenance has a major impact on illicit drug use and criminal activity, and that
these positive outcomes were related to duration in treatment (Ball & Ross, 1991;
Hubbard et al., 1989; Simpson & Sells, 1982; McGlothlin et al., 1981b; table 6).
Several studies accumulated evidence that the prescribing of oral methadone is
associated with lower rates of HIV infections for patients during treatment
(Schoenbaum et al., 1989; Novick et al., 1990) and reductions in risky injecting and
needle sharing behaviors (Ball & Ross, 1991; Selwyn et al., 1987; Darke et al., 1990).
Concerning patient characteristics, research found no good criteria as prognostic
indicators for successful drug treatment (Hubbard et al., 1989; Simpson & Sells,
1982; McGlothlin et al. 1981a; Joe et al., 1991; table 6). Patients with good
psychosocial adjustment before treatment and with good social support are more
likely to benefit But patients with poorer psychosocial adjustment included in MMT
are important from a public health perspective (HIV infection and hepatitis
prevention). In the multicenter study of Ball & Ross (1991), treatment outcome was
influenced negatively by a young age at first use of heroin, total years of drug use,
and additional cocaine use. But these patient characteristics had less impact on the
overall treatment outcome than did program characteristics (i.e. treatment policy,
treatment facilities, treatment ‘philosophy’ and location of the MMTP).
The effectiveness of MMT in observational studies of community treatment programs
has not been as impressive as that in the RCTs, indicating that half of those who
enter treatment leave within 12 months and some of those who stay continue heroin
and other illicit drugs. The proportion of continuing illicit drug use varies considerably
from one program to another (10% to 56%; table 6). Ball and Ross (1991) found that
this variability was may be due to characteristics of the patients and program
variables (treatment philosophy, offered services, national policy).
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Table 6: Observational Studies
No. Of
groups
Study
duration
Number of
subjects
Design: Results Reference
1
program
1964-
1971
17’500 Pre-Post study:
- MMT
- 1-year retention = 90%
- 2-year retention = 80%
- 3-year retention = 75%
mortality rate was 11 times higher
in patients entering detoxification
than in the MMT cohort.
Gearing &
Schweitzer, 1974
52
programs
12 months 4627 out of
44'000
patients
were
interviewed
Comparative study:
- MMT
- Therapeutic
Community
- Outpatient
drug-free
- detoxification
- Patients from MMT, Ther.
Communities or outpatient
drug free had better outcomes
than those from detoxification.
- Improvement correlated with
duration in treatment
Simpson & Sells,
1982
DARP*
USA
41
programs
Every 3-
month
interviews
11’000 Comparative study:
- MMT
- Therapeutic
Community
- Outpatient
drug-free
Retention in treatment:
- MMT = 65%
- Ther. Community = 44%
- Outpatient drug-free = 40%
- Improvement in the 3 groups
correlated with duration in
treatment
Hubbard et al.,
1984 and 1989
TOPS**
USA
3
programs
4-year
and 8-
year
follow-up
439 - MMT
- Therapeutic
Community
- active users
After leaving MMT, 54 % relapsed
to heroin use and 70% were
arrested
Anglin &
McGlothlin, 1984
California
6
programs
1-year
follow-up
633 - MMT - 71% did not inject anymore.
- Concomitant drug use in MMT
varied from 10% to 56%.
- Significant decrease of crime
days
- In the drop-out cohort, 68%
relapsed to heroin use.
Ball & Ross,
1991
USA
*DARP (Drug Abuse Reporting Program)
**TOPS (Treatment Outcome Prospective Study)
1.6.3 Risks of Methadone Maintenance Treatments
Although clear benefits have been shown from MMT, there are risks to the individual
and the community that need to be kept to a minimum through control of the
administration of methadone. When adequate control measures are not used,
patients may ingest more than their prescribed dosage, household members may
accidentally drink the patients’ methadone, and methadone may be sold or given to
persons who are non-opioid-tolerant (Perret et al., 2000). A lethal oral dose is thought
to be in excess of 40-60 mg in non-opioid-tolerant people. These risk factors can be
controlled by prescribing initial doses of 10-40 mg in the induction phase of MMT and
by giving take-home doses only to patients with a good response to treatment.
Furthermore take-home doses should be stored in child-proof containers. Deaths
associated with accidental methadone poisoning were reported, and the authors
highlighted the importance of supervised dosing to prevent methadone-related
deaths especially in the induction phase (Neeleman et al., 1997; Williamson et al.,
1997).
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1.6.4 Components of Effective Methadone Maintenance Treatments
In RCTs’ a consistant relation between higher doses of methadone (>50 mg), less
illicit opioid use, and higher retention rates in treatment was reported (Strain et al.,
1993; Goldstein et al., 1973; Johnson et al., 1992). Observational studies showed,
that the more effective clinics (in achieving significant reduction in heroin use) were
characterized by prescribing adequate doses of methadone (50-120 mg per day) with
a flexible dosing policy, and having a treatment goal of ongoing successful
maintenance rather than abstinence (Ball & Ross, 1991; Payte et al., 1993; Eap et
al., 2000; McGlothlin et al., 1981a; Joe et al., 1991; Caplehorn et al., 1994) (table 7).
Furthermore, clinics with a better quality of medical and counseling services, better
staff-patient relationships, low staff turnover rates, and better management were
more effective (Ball & Ross, 1991).
Considering the facts that opioid dependence is a chronic relapsing disorder, several
reports from clinicians suggest that abstinence from any substance (including
methadone), may not be an appropriate treatment goal for many patients (c.f. Ball &
Ross, 1991). There is also clear evidence that longer stays in treatment are
associated with better overall outcomes (Dole & Joseph, 1978; Hubbard et al., 1989;
Simpson & Sells, 1982; Ball & Ross, 1991). The reason for ending treatment is also
highly predictive. Patients who end treatment with staff approval are doing much
better than those who leave for other reasons (Des Jarlais et al., 1981; Dole &
Joseph, 1978; Simpson et al., 1982). As outlined before, relapse rates are extremely
high (70%-80%) for methadone patients once they left treatment (Anglin et al., 1984;
Des Jarlais et al., 1981; Dole & Joseph, 1978; Ball & Ross, 1991; Magura &
Rosenblum, 2001) but not higher than after drug-free residential treatments (Maddux
et al., 1992).
In many MMT, urinalyses are used to monitor patients’ illicit drug use and to ensure
that they are taking their prescribed methadone. Observational studies showed, that
the the monitoring itself does not reliably reduce illicit drug use (Havassy et al., 1981;
Stitzer et al., 1993). To reward reductions in concomitant drug use with privileges,
such as take-home methadone doses, has been shown to be effective. On the other
hand, there is no evidence that the loss of privileges has an effect on concomitant
drug use.
Table 7: Components of Effective Methadone Treatments
 Flexible but adequate dose of methadone after stabilization (usual range 50-150 mg)
 Adequate duration of treatment
 Goal of maintenance
 Rapid client-centered assessment and induction
 Psychosocial services to deal with social disadvantage and psychiatric comorbidity
 Trained staff with positive attitudes towards MMT and opioid-dependent patients
 Affordable cost of treatment
 Engagement with clients rather than punishment of continuing illicit drug use
Adapted from Ward et al., 1999, p. 223
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1.6.5 Predictors in Methadone Maintenance
Previous studies have looked at predictors of retention in treatment, but the findings
are inconsistent (Simpson & Sells, 1982; Ball & Ross, 1991; McCaughrin & Price,
1992; Magura et al., 1998). Part of the reason is that most prior studies have
focussed on “fixed”, pretreatment variables, with little or no inclusion of “dynamic”,
intreatment variables that capture treatment processes (Fig. 4). Magura et al. (1998)
demonstrated in a sample of 1206 admissions to MMT that intreatment variables are
better predictors of retention than pretreatment variables. Only two of 16
pretreatment variables (age, involved with criminal justice), compared with five of six
intreatment variables (adequate methadone dose, individualized interventions,
cooperation, continued heroin and/or cocaine use) had significant effects on
retention. These results suggest that events during treatment are crucial for patient
retention.
1.6.6 Ancillary Interventions
The traditional role of counseling in MMT as delivered in specialized clinics in the
USA has been case-management and crisis assistance to help patients resolve
difficulties associated with their opioid dependence. Comorbid psychiatric disorders
are not usually dealt with by counselors in such clinics (Mattick et al., 1998). When
MMT is managed by a general practitioner (like in the UK, Switzerland, the
Netherlands), the general practitioner usually provides this routine counseling or
referrers the patient on to appropriate services for other areas (e.g. financial,
employment, parenting, legal, accommodation).
There has been considerable debate over the role of counseling in maintenance
substitution programs and the association between amount, quality of medical
services, counseling and treatment outcome is not clear (Ball & Ross, 1991; Joe et
al., 1991; McLellan et al., 1988, 1993). The model of MMT that has been effective in
most studies has usually been clinic-based, and has included counseling, even
though MMT without formal counseling has becoming increasingly common
throughout the world (e.g. UK, Australia, the Netherlands, Switzerland, and Spain)
but has “not been formally evaluated in Europe” (Farrell et al., 1994, p. 999). Recent
studies with randomized designs have failed to show consistently that the provision of
additional services, including counseling, achieve better outcomes than MMT without
counseling (Mattick et al., 1998). Intensive services seems to render treatment more
expensive with only marginal improvements in effectiveness (Kraft et al., 1997).
Nevertheless, the following findings remain important for clinical practice. The early
practitioners of MMT argued that most patients’ problems resulted from the heroin-
seeking habits and their low socio-economic status (Dole & Nyswander, 1967;
Newman et al., 1979) and highlighted the importance of developing an empathic
alliance between the specialist respectively the general practitioner and the patient.
In 1991 Ball & Ross for the first time provided a detailed summary of what counselors
actually do on a day-to-day basis in MMP, and how those services affect their
patients. They found that the principal activities of a counselor can be described by
10 categories: Case management; liaising with other social services; assessing new
admissions; one-to-one counseling; brief contacts; group therapy; family couples
therapy; assessment of psychological problems; vocational counseling and
14
education. Most surveyed MMP/ clinics had regular (on average fortnightly) one-to-
one counseling sessions with an average duration of 37 minutes.
The Treatment Outcome Prospective Study (TOPS; Hubbard et al., 1989) has also
provided some information on counseling services delivered in 17 methadone
maintenance units, and also the national survey of Calsyn and colleagues (1990). In
these surveys 50 to 67 percent of the persons employed at MMT were counselors
(one third of them were ex-addicts). Furthermore they reported 78 percent of the
patients receiving mostly individual counseling, and only 7 percent receiving group
therapy. Group sessions tended to be topic-oriented rather than generally
therapeutic. Only the observational study of Joe et al. (1991) found an increase in
retention (13%) as measured as survival rate for more intense psychological
services.
In other countries (e.g. Australia, UK, Switzerland) the professionals most commonly
employed in MMT are physicians and nurses. And in the mid eighties, with the
spread of HIV, a lot of physicians in primary care enhanced their engagement for
opioid-dependent patients. In Switzerland, according to the National Treatment
Guidelines of the Federal Office of Public Health, such services should be available
for patients who need them, either at the clinic or by referral, and carried out by
qualified psychiatrists, psychologists and social workers (Bundesamt für Gesundheit,
Methadonbericht, 1995).
Taken together, the evidence from methadone treatment studies suggests that
counseling should be available to all patients, and tailored to patients’ needs. All
ancillary services should be offered on the basis of the patient freely consenting. One
possibility to help professionals to decide if the patient need additional counseling is
the semi-structured interview “Addiction Severity Index” (ASI) as developed by
McLellan and colleagues (1980). This interview is widely used in the United States
and in Europe.
1.6.7 Psychotherapy in Methadone Maintenance Treatment
Counseling approaches and psychotherapy, such as motivational interviewing (Miller
& Tonigan, 1996), relapse prevention programs (Marlatt & Gordon, 1985) and social
skills training (Myers & Smith, 1995; Monti et al., 1989), which are based on cognitive
behavioral therapies, are frequently used in MMT and found to be effective. More
intensive psychotherapy like the Interpersonal Therapy (Rounsaville et al., 1983) can
be beneficial to people with concomitant affective disorders (e.g. depression,
anxiety). Recent Behavioral Therapies combine these methods (e.g. Relapse
Prevention & Contingency Management [RP & CM]) or develop new therapeutic
interventions for specific patient populations (e.g. Dual Diagnosis Relapse Prevention
(DDRP). A recent study compared Motivational Enhancement Therapy (MET) and
Drug Counseling (DC) in methadone patients with a high versus a lower dose of
methadone (Woody & McLellan, 2002). No clear advantage was seen for MET as
compared to DC, but a better outcome for patients with higher methadone doses
(Woody & McLellan, 2002; Carroll et al., 1994). Most of these psychotherapies are
based on two important theoretical assumptions: the behavioral change model of
Prochaska & DiClemente (1992), and a continuous, long-term treatment of opioid-
dependent individuals (Petzold et al., 2000).
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1.6.8 Methadone Maintenance in General Practice
Although rapid expansion of methadone programs has occurred in many countries
(e.g. Spain, Switzerland, Australia, The Netherlands, UK), there are few studies on
the impact of office-based treatment on treatment success. On the other hand there
have been repeated calls from experts and clinicians for expansion of availability of
methadone maintenance in several countries (United States, Germany, France,
Sweden). These countries want to expand MMT to treatment providers in primary
care settings like general practices (Weinrich et al., 2000; Lewis et al., 1999).
Moreover, this would be a more efficient and less expensive way of delivering
treatment, than in specialized clinics. Furthermore, this way could be more attractive
to patients than the current models. “One alternative is to have general practitioners
as prescribers and community pharmacies as dispensers of methadone, as in the
UK, the Netherlands, in Spain and in some regions in Switzerland. However, new
models for delivering MMT must be “properly assessed to ensure that the
demonstrated effectiveness of the traditional treatment model is retained” (Farrell et
al., 1994, p. 1000).
Until now, only one Randomized Controlled Trial exists, comparing methadone
maintenance patients in primary care (n = 22) versus in specialized clinics (n = 24)
(Fiellin et al., 2001). Results indicate no differences between groups concerning illicit
heroin use or use on health or social services. Patients in primary care were
significantly more satisfied with their treatment compared to patients in clinic.
Observational studies of patients receiving prescriptions in general practice have
shown that they value care in general practice (Leaver et al., 1992; Speed et al.,
2000). As Lewis states, “potentially primary care can allow easy access, holistic care
for all medical problems, building of long term relationships, and avoidance of the
stigma attached to attendance at drug clinics” (1999, p. 7).
On the other hand, the provision of MMT in specialized drug clinics can show some
advantages for the drug users: First, the greater experience of the doctors and
secondly, they have more time available (Glanz, 1986), thirdly, they have specialists
for the treatment of psychiatric comorbidities (affective disorders, psychosis,
anamnestic attention deficit syndrome, and personality disorders) and somatic
comorbidities (hepatitis, HIV, liver disease).
One British survey indicated, that most general practitioners felt “inadequately trained
to prescribe methadone”, but would be encouraged to be involved in treatment if
there were “better support from specialist services existed” (Davies & Huxley, 1997,
p. 1173). A National Treatment Outcome Research Study (NTORS) in the UK
recently compared six month treatment outcomes for patients receiving methadone
maintenance either in a specialist clinic or general practice (Gossop et al., 1999). The
two different settings showed comparable results, and patients were similar in age,
sex, length of dependence, injecting habit, other drug use, and previous treatment
attempts. Another study compared patients’ characteristics and treatment outcomes
in primary (n = 89) or secondary care settings (n = 36) in a retrospective review of
patient records. Patient characteristics were similar at the start of the treatment, and
the proportion of patients with good outcomes were equally in either setting (Lewis et
al., 2001). Langendam and colleagues (1998) compared 7 different methadone
dispensing sites in a large cohort study (n = 444) in Amsterdam and found lower
methadone dosages for patients treated by the general practitioners. Taken together,
there are only a few observational studies and one RCT comparing MMT in primary
care with MMT in specialist clinic settings.
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1.7 Methadone Maintenance Treatments in Switzerland
In Switzerland, opioid addiction constitutes a major public health problem. Federal
drug treatment policy in Switzerland consists of four pillars: harm reduction, therapy,
prevention and repression (Bundesamt für Gesundheit, 1999; Klingemann, 1996).
The organization and regulation of MMT varies widely from one canton to another
and there are no explicit federal treatment guidelines for MMT to date. In contrast,
countries like Australia and the United States have high levels of regulation and
structured programs (Farrell et al., 1994; Parrino 1993). Some 30'000 persons are
dependent on heroin and/or cocaine. Yearly, some 100 intravenous drug users die
from AIDS, and another 200 die from other causes (suicide, incidents, liver disease,
heroin overdoses, and intoxication from polydrug use) (compare figure 1). In the
countries of the European Union (EU), approximately 1 to 1.5 million persons are
dependent on opioids (Vader et al., 2002). In the EU 300'000 opioid dependent
patients are actually in a MMT (Reisinger, 1997). In Switzerland, more than 60% of
opioid addicts are engaged in some kind of addiction treatment: 2100 patients in
inpatient abstinence-oriented community-based treatments, more than 15'000
patients in MMTs, and more than 1000 in medical prescriptions of narcotics [heroin]
(Bundesamt für Gesundheit, 1999). Thus, considering the overall spectrum of all
available treatments for opioid dependence in Switzerland, MMT play an important
role (Hermann, 2001). The first MMTP started in the late 70ties in Geneva, Basel and
Zurich. The number of MMTs in each canton are displayed in figure 2. 25 out of 26
cantons provide MMT places for opioid dependent subjects. Overall a total of 18'000
MMT treatment places*, thus 250 MMT places for 100'000 inhabitants. In Basel, the
ratio is high, with 588 available MMT places for 100'000 inhabitants.
Figure 2: Results from the Swiss National Methadone Statistics
Adapted from: act-info, “Nationale Substitutionsstatistik für das Jahr 2000”, Bundesamt für
Gesundheit, Bern, 2000. The number of 18'000 MMT places corresponds to a total of approximately
15'000 patients.
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1.7.1 Review of the Swiss Literature on MMT from 1995 to 2004
The review of the Swiss literature since 1995 by Rehm and colleagues (2001),
included all published articles (controlled trials, reports from health authorities, and
clinics) on MMT in Switzerland. Articles about detoxification with methadone were
excluded. Only reports about methadone maintenance were included in the review,
with particular interest to its effectiveness and cost-effectiveness in different clinical
settings: general practitioners, psychiatric clinics and hospitals, counseling agencies,
low threshold institution, and prisons. The review indicates that although the results
of most studies favour methadone substitution treatments, they are often plagued by
problematic methodological pitfalls, in particular, lack of an adequate control group.
There are two exceptions, the study of Petitjean at al. (2001), and Ladewig et al.
(1998). The review summarizes which indication criteria were used in the studies,
which dosage schedules, insisting that studies with higher methadone doses appear
to have better success rates than those with lower doses (Liechti et al., 2000). The
report concludes with a recommendation for more high quality studies on
effectiveness and cost-effectiveness on the global system level of MMT, for a re-
examination of dosage schedules (in particular in relation to individual differences in
methadone metabolism), consideration of psychiatric co-morbidities, and finally a
better differentiation between indication criteria for substitution treatment and
abstinence-oriented treatment. An additional literature review on Swiss MMT from
2001 to 2004 revealed two important reports, indicating better treatment retention in
patients treated in general practice versus patients treated in specialized clinics
(Petitjean & Schaller, 2002b; Falcato et al., 2002).
1.7.2 Review of International Literature on MMT from 1995 to 2004
The international literature review by van Beusekom and colleagues (2001) analyzed
guidelines for methadone maintenance treatment from 17 different countries (except
Switzerland), examining elements as admission criteria to MMT; initial, maximal and
allowable take-home doses; and treatment services. The report concludes, that
important advances have been done in the last 5 years, in particular concerning the
pharmacokinetics of methadone (Eap et al., 1996; 2000). Some patients need higher
methadone doses due to lower plasma concentrations. Furthermore, previous study
results about the effectiveness of MMT have been confirmed in several studies, in
particular studies indicating the effectiveness of higher methadone doses. Separate
report sections outlines the needs of specific patient subgroups: patients with HIV-
infection, hepatitis or tuberculosis, polydrug users, pregnant opioid dependent
women. Furthermore the need for psychosocial treatment and other motivational
interventions, and recommendations for treatment guidelines development. The
guidelines are summarized according to the main phases of methadone treatment
(initiation, maintenance and cessation of treatment). An additional international
literature review on office-based MMT from 2001 to 2003 revealed two important
studies, indicating good treatment outcomes for stable patients treated in general
practice versus patients treated in specialized clinics (Gossop et al., 2003; Fiellin et
al., 2002). A major purpose of researchers in the addiction field in the United States
is, to develop office-based pharmacotherapies for opioid dependence (Fiellin &
Barthwell, 2003).
Before starting the present study, a complete review of the literature was performed
in May 2002 (MEDLINE, Cochrane Review), and main reports of the existing Swiss
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literature (Rehm et al., 2001; Van Beusekom et al., 2001; Hermann, 2001) were
reviewed. An additional review of the literature was performed in May 2004.
1.8 Methadone Maintenance Treatments in the City of Basel
In Basel, a city of 188’000 inhabitants, opioid addiction began to be recognized as a
health problem during the 1970s. 1976 the first methadone maintenance treatment
programs (MMTP) were developed, based on the work of Dole, Nyswander and
Kreek in New York (1966). Another small treatment program with codeine was also
developed. The first MMTP were mainly carried out in specialized addiction treatment
units in psychiatric clinics. Some engaged general practitioners treated also a few
patients from the beginning. In Switzerland the prescription of oral methadone to
patients dependent on opioids is regulated by federal laws since 1975. Only
physicians holding a special permission may prescribe methadone. Generally,
methadone maintenance is provided for patients aged 18 years or older who are not
willing to undergo abstinence oriented treatments and incorporates individualized
medical, psychological and counseling services. The most widely accepted objectives
of methadone maintenance are: to reduce harmful opioid and other drug use, to
improve the health of clients, to help reduce the spread of blood-borne diseases, to
reduce deaths associated with opioid use, to reduce crime associated with drug use,
and finally to facilitate an improvement in social functioning.
However, as a general treatment philosophy methadone programs in Basel favored
long-term methadone maintenance, but always with the objective of abstinence.
Patients’ names are reported to the local authorities and treatment performance to
specialized evaluation agencies. As a rule, since the mid nineties, there are no
restrictions regarding dosing and treatment duration, but general methadone
maintenance treatment guidelines (Stohler et al., 1995). Methadone treatments are
paid for by health insurance. Nursing staff or pharmacist administer the medically
prescribed dose of oral methadone daily on-site. After an induction period,
maintenance methadone doses can be delivered as take-home doses. The
methadone administered is a 2 percent methadonehydrochlorid solution (Racemat).
Methadone tapering procedures can be carried out in an inpatient unit or as an
outpatient detoxification. Dose increases and decreases are decided on the doctor-
patient level. Subjects receive medical examination and individualized psycho-social
counseling. In the city of Basel, maintenance prescribing has always followed, from
the beginning, a model of shared care. Maintenance prescribing and detoxification
interventions are undertaken in a planned manner in collaboration with the patient
and other parties, such as a general practitioner liaison physician, as appropriate.
Shared care arrangements are important if the patients treated in primary care need
psychiatric, somatic interventions in clinic or if the general practitioner is absent from
his office.
The health authorities, the police and experts in addiction estimate that approximately
2000 drug users live in Basel. Since the late 1980s, with the advent of the AIDS
epidemic in Switzerland, risk reduction and needle exchange programs and also an
easier access to MMTP became available. The inclusion criteria respectively
indication criteria for a MMT are nowadays, an opioid dependence according to DSM-
IV (APA, 1994), aged 18 or older. The number of patients in methadone treatment
has more than doubled since 1990, rising from 500 to 1019 in 2000 (Petitjean et al.,
2000; Fig.  3).
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Figure 3 shows an increase of MMT in Basel, from 1986 to 1994  parallel to the
advent of the AIDS epidemic. The consequence of AIDS was an easier access to
methadone programs. Since 1997, the MMT are stabilized at an average of 1000
patients.
Figure 3: Number of Patients in MMT in Basel between 1980 and 2001
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1.9 Treatment Outcome Evaluation of Methadone Maintained Patients in Basel
In contrast to the United States, where large-scale studies (e.g. TOPS [Treatment
Outcome Prospective Study; Hubbard et al., 1989], Ball & Ross, 1991; DATOS [Drug
Abuse Treatment Outcome Studies; Grella et al., 1999]) focus on long-term MMT
outcomes, MMT in Switzerland has received no formal multi-site evaluation to date.
Nevertheless, the idea of a Swiss multi-site MMT evaluation was developed in the
early 1990s, and several expert panels have been organized, sponsored by the
Federal Office of Public Health (FOPH) in Berne. The consensus of these meetings
was the development of a nationwide standardized questionnaire, which was utilized
by four cantons (Basel, Zurich, Geneva, and Tessin) in the last 10 years, and
continuously adapted, making comparisons difficult. In the last decade, several
reports have been published by the health authorities and addiction research units in
Geneva (Petitjean & Schaller, 2002 b), Zurich (Falcato et al., 2002), Tessin (Cerutti &
Cassis, 2004), and Basel (von Bardeleben et al., 1993; Petitjean et al., 2000 and
2002 a). Actually an expert panel from the Swiss FOPH tries to develop a multi-site
MMT evaluation. This work is still going on (Vader et al., 2002).
20
In 1992 Ladewig and colleagues started to analyze the MMT at the two specialized
clinics, the psychiatric university hospital and the psychiatric university policlinic in
Basel, by sending a standardized questionnaire to the physicians. At that time, the
general practitioners were not included in the data collection. But with the growing
number of MMTs, the health authorities and research groups decided to include all
patients registered in a MMT in Basel in a survey. Like the National Treatment
Outcome Research Study (NTORS) in the UK, outcomes of patients treated in
specialized drug clinics and in general practices (Gossop et al., 1999; 2003) were
analyzed by face-to-face interviews.
To understand the complexity of treatment evaluation it is very helpful to look at the
model of Ball & Ross (Fig. 4; 1991).
Figure 4: Four Domain for Treatment Evaluation (Ball & Ross, 1991)
From: Ball J.C.& Ross A. (1991).
Legend: In the present “four domain schema”, the first domain represents the heterogeneity of the
patients [1], the second domain the treatment location/ facilities [2], the third domain the services
provided [3], and the forth domain the treatment outcomes [4]. Thus, the outcomes can be understand
as a combination and interdependence of the domains [1], [2], and [3].
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Methadone maintenance treatment programs or general practices treat different
subgroups of patients, these patients are treated in different settings, obtain different
services (e.g. medical, psychological, counseling), and the patients at each treatment
facility can have different outcomes. The question remains, which factors account in
which proportion for a “good” or a “bad” treatment outcome? And how can we
measure that ? This conceptual model was very important for the development of the
research question and the interpretation of the results of the present study.
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2. Methods
2.1 Research Question
The present study reports the outcomes of patients who received methadone
treatment in either a specialized clinic or in a general practice setting. The overall
objective was less to show that methadone treatment works, but more for what it tells
us about how it works. We explored the major factors related to treatment outcomes.
The specific research questions were: length of stay in treatment, one-year retention
in treatment, concomitant drug use in the past 30 days, intravenous drug use in the
past six months, average values of prescribed methadone doses, the amount of
offered and attended consultations, HIV seroprevalence rates, hepatitis rates, and
HIV risk behavior. These specific research questions were first analyzed for the total
sample at two time points, and secondly by comparing patients treated in general
practice versus in specialized outpatient clinics.
2.2 Hypotheses
For answering the main research questions, the following hypotheses were
developed for the total sample:
A1) Data Analysis of the Total Sample (n = 660): Overall Outcome
H0: Does methadone maintenance as a general modality work in daily clinical
practice? The objective is to demonstrate the clinical significance and the stability of
treatment outcomes (retention, concomitant drug use) over time by a one-year follow-
up.
A2) Data Analysis of the Total Sample (n = 660): Frequency of Consultations
H1: Patients attending more consultations have a better retention in treatment, and
less illicit drug use.
H0: there is no association between the amount of attended consultations and
retention in treatment; there is no association between the amount of attended
consultations and illicit drug use.
A3) Data Analysis of the Total Sample (n = 660): Compliance
H1: Patients with a “good cooperation” [GC] (compliant patients) have a better social
functioning, less concomitant drug use, less intravenous drug use, a lower rate of
multiple substance use, and a lower rate of dual diagnosis than those with an
“unsatisfactory cooperation” [UC] (non-compliant patients).
H0: There is no association between patient characteristics, patient behavior and
compliance.
Definition:
[GC] = patients attending all scheduled consultations, or missed only one out of all scheduled
consultations.
[UC] = patients missing more than one scheduled consultation.
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The following hypotheses were developed for the comparison between patients
treated in specialized clinics versus patients treated by general practitioners:
B1) Comparison Between Patients in General Practice and in Specialist Clinic
Settings: Overall Outcome
H1: patients in general practice have better outcomes (retention, concomitant drug
use) than those treated in specialized clinics.
H0: patients outcomes in general practice are as good or worse than those treated in
specialized clinics.
B2) Comparison Between Patients in General Practice and in Specializist Clinic
Settings: Consultations
H1: Patients in general practice attend more consultations than those in specialized
clinics.
H0: Patients’ compliance in general practice is as good or worse than in specialized
clinics for the main outcome variable, number of attended scheduled consultations.
2.3 Treatment Programs
The present study is a prospective cohort study of patients recruited from all MMT
programs in the City of Basel. The clinic sample was drawn from two state
methadone clinics, and one private clinic. The GP sample from 120 GP practices.
Two out of three specialist multimodal MMT centers are located in inner-city, one
center is located at the border. The GP practices are located over the whole city. In
the shared care system (chapter 1.8), two thirds of the general practitioners take
responsibility for the prescription of methadone, provide medical care and
consultations as required, and allow their patients to take the methadone on site in a
authorized pharmacy. One third of the GP sample dispense methadone in their
practice. The specialized clinics were providing MMT to much larger number of opiate
dependent patients, including methadone prescription, dispensing and providing
medical, psychological, and social services. The MMT programs were purposely (not
randomly) chosen for participation.
There were no differences between GPs and clinics in the dispensing of methadone.
Daily dispensing was as frequent among the GP agencies (21.5%) than for the clinics
(20.9%).
2.4 Study Population
The present study sample comprised 660 patients, of whom 460 patients received
methadone treatment from specialist drug clinics and 200 from GPs. This sample
was constructed in the following ways. An initial sample of 815 patients was recruited
from the clinic and GP programs in March 2000. Patient inclusion criteria for the
prospective cohort study were: men and women, aged 18 or older, fulfilled DSM-IV
criteria for heroin dependence (304.02: APA, 1994), maintenance with oral
methadone, registered in a MMT for at least three months, inhabitant of the Canton
Basel. The exclusion criteria were: patients with another maintenance medication
than methadone (e.g. buprenorphine, morphine, codeine, naloxone), patients with
less than 1 mg/d of prescribed methadone, patient with an incomplete questionnaire
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(missing values like patient code, age, gender, dispensing site). Each client
completed and signed a consent form to allow participation in the study. Relevant
Human Research Ethics Committees approved the cohort study retrospectively
(Ethikkommission beider Basel, 18.8.2003, see Appendix).
From the patients eligible for the 1-year follow-up study, a stratified random sampling
procedure was used to include approximately the same percentages within the
treatment modalities (SPSS sampling procedure). A total sample of six hundred and
sixty patients was selected (table 8). The proportion of evaluable subjects did not
differ significantly among treatment modalities: 83% from the GP sample, and 80%
from the clinic sample (chi square = .894, df = 1, p = 0.199). Evaluable subjects were
significantly older than the non-evaluable subjects (33.7 vs. 32.3 years; ANOVA; F
(1,814) = 5.527, d = 1, P = 0.019), but otherwise did not differ in any baseline subject
characteristics (e.g. age, gender) [data not shown]. The first survey consisted of 660
outpatients with 641 patients in the in-treatment cohort and 19 in the admission
cohort. At 12-month follow-up, 486 patients (73.6% of the 660 patients from the first
survey) were successfully interviewed in March 2001 (table 9). The study sample (n =
660) was of sufficient size to give good accuracy in statistical analysis, and the
follow-up interviews provided information about the stability of the MMT.
Table 8: Design of Data Collection for One Year
Patients at the three programs and the GPs Outcome for patients
- review of patient
register
- census of patients
(31.3.2000)
Participants:
3 specialized clinics
and 70 GPs
- return of
anonymous data
to the research
group
First survey (t1)
- 660 patients*
- A sample of 60 or
more at each
program
-   Instrument:
Standardized
questionnaire
Second survey (t2)
- 486 patients
- Still in treatment
(486)
- Drop-outs
(171)
Change t1 to t2
- Drop-outs
- Illicit drug use
- IV drug use
- Number of offered and
attended consultations
- Methadone doses
- Other characteristics
- return of census
findings to
programs and GPs
*(A) in-treatment cohort n = 641
(B) admission cohort n = 19; inclusion criteria, at least 3 months in MMT.
2.5 Measures and Procedures
Data were collected by structured face-to-face interviews at baseline and at one-year
follow-up. The data collection procedures included confidential face-to-face
interviews with a standardized questionnaire (see Appendix), and compilation of
required data from case register records. The collected data were deemed
confidential, and the results were not made available to either the treatment or the
administrative staff of the respective program or general practice. Data was only
available for the research group (a physician, a clinical psychologist). Anonymous
data was kept in the Addiction Research Unit of the Psychiatric University Hospital in
Basel.
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The questionnaire  contained items and scales developed specifically for this project,
as well as measures adapted from published instruments. Subjects were interviewed
by the physician responsible for the treatment at the specialized clinic or at  the GP
practice. Thus, the interviews were carried out in the natural visit/consultation
context. If the subject did not reach the appointment, the physician filled out the
questionnaire by examining the case report. The interview consisted of two pages of
questions (see appendix) and provided measures of social and demographic
variables, a section concerning actual methadone treatment variables, a section
about consultations in the past 6 months, a section about lifetime illicit drug use and
in the past 30 days (heroin, cocaine, alcohol, non-prescribed benzodiazepines)
adapted from the Addiction Severity Index (McLellan et al., 1980), a section about
hepatite serostatus, and a section about health risk behavior. Self-reports about illicit
drug use should ideally be corroborated by urinalysis or other means where there is
reason to believe that self-reports are biased in a way that undermines reported
findings. There is no social pressure to lie and we can be confident, that the results
about concomitant drug use are quasi objective. Additionally there were no financial
resources available for using urine screening in the total sample.
Time in treatment was assessed in terms of number of years for which the patients
remained in contact with treatment providers. These data were obtained directly from
the treatment programs, as well as the reasons for leaving MMT. Measures of
counseling sessions attended were obtained during interviews conducted with
patients at baseline and at one-year follow-up.
2.6 Statistical Analyses
According to Bortz (1999), the proportion of missed variables had not to exceed 40
percent. Following this assumption, all assessed variables could be included.
Student’s t-test was used for continuous variables and the chi-square-test for
categorical variables. Baseline/ follow-up comparisons for patients are presented
using paired data sets. Changes for categorical dare are assessed with the McNemar
test. A repeated measure analysis of variance was carried out on outcome measures.
Time in treatment was assessed by Kaplan Meier survival analysis. Differences
between the two groups were measured by a log rank test. Unless otherwise stated,
all tests were two-tailed, and an  level of 0.05 was considered significant.
Cox regression procedures were used to compare retention times controlling for
baseline differences between the two populations (age, length in treatment). To
analyze self-reported drug use in the past 30 days prior interview, a missing
information from patients who dropped out of the study before the end were
considered as positive. Data analysis were first conducted on the 660 enrolled
patients (intent-to-treat analysis [ITT-analysis]; all observed cases), and separately
for 486 of the original 660 patients who completed the one-year follow-up (completer
analysis).
For treatment x time effects, data were analyzed according to a two-factor repeated
measures analysis of variance (ANOVA). Levene’s test of equality of variance
showed that ANOVA assumptions had not been violated for any factor except for
‘self-reported cocaine use in the past 30 days’. All statistical analyses were
performed using SPSS statistical software, version 11.
3. RESULTS
3.1 TREATMENT OUTCOMES OF THE TOTAL SAMPLE
3.1.1 Sociodemographic Characteristics of 660 Methadone Maintenance
Patients
Of the six hundred and sixty patients, 19 were in the admission sample (up to 0.49
years), 227 were in the average stay sample (0.50-4.49 years) and 414 were in the
long-term sample (4.5+ years). The baseline characteristics of all patients by gender
are shown in table 9.
69% of the cohort were male, 31% were female. Age at first interview (t1): The 660
patients were primarily middle-age adults, with 74 percent of them being between 25
and 39 years old. Only 5.9 percent were under age 25. 20 percent were 40 or older.
Their mean age at time of first interview was 34.4  6.4 years (men 34.4  6.4 years;
women 33.8  6.3 years; Fig. 5).
Figure 5: Age Distribution (n = 660)
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addiction prior to their entry in a MMT. Their mean age at the beginning of the MMT
was 28.4  6.6 years, with a significant gender difference (table 10; women 27.5
years versus men 28.8 years; P = 0.023).
Basic demographic characteristics of 660 methadone maintenance patients were
similar between gender, except for marital status, with a significantly higher
percentage of unmarried men (77.6% versus 64.6%; Mann-Whitney-Test, Z = -3.447,
P = 0.001), and significantly more women with children (23.3% versus 47.8%; Chi
square, df = 1, P = 0.001; table 9).
Table 9: Demographic Characteristics of 660 Methadone Maintenance Patients
Variable Male
n=456
Female
n=204
Total (P1)
n=660
P-value
Age (years) (Mean  SD)
Range
Median
95% CI
34.7  6
20 – 59
34.2
34.1 – 35.3
33.8  6
20 – 49
33.2
32.9 – 34.7
34.4  6
20 – 59
33.7
33.9 – 34.9
ANOVA
0.103
Sex (M/F) 69 % 31 % 100 %
Marital status:
Unmarried
Married
Divorced/ separated
Widowed
77.6 %
7.8 %
14.3 %
0.3 %
64.6 %
11.8 %
20.0 %
3.6 %
73.7 %
9.1 %
16.0 %
1.2 %
Mann-
Whitney
0.001
Parenthood:
With at least one child 23.3 % 47.8 % 29.2 %
Chi2
0.001
Nationality:
Swiss
European Union and other countries
85.8 %
14.2 %
89.5 %
10.5 %
86.9 %
13.1 %
Chi2
0.128
Education:
School absolved
apprentice
Higher degree school/ University
43.3 %
52.2 %
4.5 %
51.9 %
46.6 %
1.5 %
45.8 %
50.6 %
3.6 %
Mann-
Whitney
0.060
Education: Swiss population, 25+ years*:
School absolved
apprentice
Higher degree school/ University
8.8 %
57.0 %
34.2 %
15.9 %
66.8 %
17.3 %
19.0 %
56.8 %
24.2 %
Employment history:
employed
social welfare
disability annuity
32.8 %
21.4 %
45.8 %
21.6 %
30.2 %
48.2 %
29.4 %
24.0 %
46.5 %
Mann-
Whitney
0.061
Employment: Swiss population,25+ years*:
employed
unemployed
unemployed long term
disability annuity
52 %
2 %
15 %
3 %
*Bundesamt für Statistik (2002)
Nationality: 86.9 percent of the 660 patients were Swiss, and 13.1 percent were from
other countries (table 9). In general, minority group position did not differ between the
programs. However, there were considerably less patients from minority groups than
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in the general population in the city of Basel (13.1% versus 27.7%; Bundesamt für
Statistik, 2002, p. 28).
Education: When considering the life history of these 660 addicts in greater detail, we
can see, that the years of formal education of the addict patients were considerably
below that of the general Swiss population (Bundesamt für Statistik, 2002; table 9).
Respectively the number of subjects with “absolved school” as highest degree of
education was considerably higher compared to the general Swiss population (45.8%
versus 19%). Looking at the proportion of subjects with an higher degree school or
university, the difference is dramatic with a ratio of 3.6% versus 24.2%. These data
demonstrate, that only a small group of subjects reach a higher school degree,
probably due to the impact of the addiction on these areas. The proportion of missing
values for this variable was quite high (33%), indicating a high proportion of the
physicians responsible for the MMT having no idea of the education level of their
patients.
Employment Status: When considering the life history of these 660 addicts in greater
detail, we can see, that the proportion of employed patients was considerably below
that of the general Swiss population (Bundesamt für Statistik, 2002; table 9, 29.4%
versus 52%). About a third of all patients are employed, 24% live from the social
welfare (including unemployed long term), and most of them have a disability annuity
(46.5%, table 9). The proportion of missing values for this variable is quite high
(29%), indicating  that a high proportion of the physicians have no idea of the
employment status of their patients. At 12-month follow-up, the sociodemographic
variables were very similar.
3.1.2 Drug Use History
Variables about drug use history were available for 66% of the cohort. Patients were
asked, about the age of onset of drug use. We got no information about the age at
onset of drug dependence.
Most patients had a long history of regular heroin use. The early age at which opioid
use commonly began was a crucial event in these patients’ lives. With few
exceptions, the onset of daily intravenous injections set the stage for a deviant
course of life that was proved difficult to change. With respect to early onset, almost
two-thirds had began use of heroin between 16 and 21 years  (table 10; Fig. 6). The
highest incidence years were ages 18 and 20.
Figure 6: Age at Onset of Opioid Use (n = 434)
Concerning the onset of cocaine use, half of the cohort had began use of cocaine
between 16 and 20 years (table 10, Fig. 7). The highest incidence years were ages
17 and 20.
Figure 7: Age at Onset of Cocaine Use (n = 434)
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Concerning drug use history, there were no significant gender differences for onset of
heroin, cocaine, cannabis, alcohol or benzodiazepine use (table 10).
Looking at the mean age of first heroin use (19.7  5 years) and the mean age of
entry in a MMT (28.4  7 years), we can observe a period of approximately 8 years
before getting enrolled in a MMT. Opioid dependent women were significantly
younger when they entered a MMTP for the first time, compared to men (27.5    7
years versus 28.8  6 years; ANOVA, df = 1, F (1, 656) = 5.183, P = 0.023; table 10).
Table 10: Drug Use History of 660 Methadone Maintenance Patients
Variable Male
n=456
Female
n=204
Total (P1)
n=660
P-value
Age (years) (Mean  SD)
Range
Median
95% CI
34.7  6
20 – 59
34.2
34.1 – 35.3
33.8  6
20 – 49
33.2
32.9 – 34.7
34.4  6
20 – 59
33.7
33.9 – 34.9
ANOVA
0.103
Age at admission to methadone
maintenance treatment
Range
95% CI
28.8  6
16 – 54
28.2 – 29.4
27.5  6.6
16 – 46
26.6 – 28.4
28.4  7
16 – 54
27.9 – 28.9
ANOVA
0.023
Age at first heroin use
Range
95% CI
19.9  4
12 – 43
19.4 – 20.4
19.2  5
11 – 42
18.3 – 20.1
19.7  5
11 – 43
19.2 – 20.1
ANOVA
0.151
Age at first cocaine use
Range
95% CI
21.5  5
13 – 45
20.8 – 22.1
20.9  5
12 – 41
20.0 – 21.8
21.3  5
12 – 45
20.8 – 21.8
ANOVA
0.311
Age at first cannabis use
Range
95% CI
15.7  2
10 – 27
15.3 - 16.1
15.3  3
10 – 25
14.6 - 16
15.6  3
10 - 27
15.2 – 15.9
ANOVA
0.372
Age at first alcohol use
Range
95% CI
15  3
8 – 25
14.6 – 15.5
15.3  4
6 – 35
14.2 – 16.4
15.1  3
6 - 35
14.7 – 15.6
ANOVA
0.557
Age at first benzodiazepine use
Range
95% CI
23  6
6 – 42
21.9 – 24.3
21.7  6
12 - 40
20 – 23.4
22.6  6
6 - 42
21.7 – 23.6
ANOVA
0.192
Proportion of patients with
intravenous drug use
(lifetime prevalence)
342 (75) 165 (81) 508 (77) Chi2
0.104
89 percent of the patients had a multiple substance use before entering treatment.
That is, multiple substance use seems to be the norm rather than the exception,
leaving only 11% of the patients with a mono substance abuse of heroin (Fig. 8).
85% had a lifetime use of both heroin and cocaine. Both cannabis and alcohol were
extensively abused prior to MMT: 52% had a a lifetime use of cannabis, 48% of
alcohol, 33% a lifetime use of benzodiazepines,  and 15% of amphetamines.
As shown in figure 8, before entering in a MMT, 36.2% of the patients had used two
substances,  7.6% had used three substances, 11.2% four substances, 20.6% five
substances, and 13.5% six substances (Fig. 8).
Figure 8: Multiple Substance Use before Treatment (n = 434)
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.1.3 Somatic Health State of 660 Methadone Maintenance Patients
ne section of the questionnaire asked questions about infectious diseases like HIV
eropositivity, hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus
HCV). A third of the physicians did not fill out this part of the questionnaire or wrote
unknown HIV state” and “unknown “hepatitis state” in the first interview.
he prevalence rate of HIV seropositivity was 8.6 percent for the total sample (table
1). These results were similar to those reported in 1999 for all patients in a MMT
9.4 percent; Petitjean et al., 1999). Women had a significantly higher HIV prevalence
ate than men (Chi2 = 12.373; df = 1; P = 0.002). The physicians responsible for the
reatment reported, that 20 percent of the HIV infected patients had AIDS. They also
eported, that an approximate of 70 percent of HIV infected were treated with a
etroviral medication. At 12-month follow-up the prevalence rate of HIV seropositivity
as 10.9 percent (table 12).
able 11: HIV Seroprevalence in MMT at t1 by Gender
2000
t1
ariable Male
n = 456
Female
n = 204
Total
n = 660
IV seropositive (N/%) 29 (6.4) 28 (13.7) ** 57 (8.6)
IV negative (N/%) 299 (65.6) 111 (54.4) 410 (62.1)
nknown state (N/%) 128 (28.0) 65 (31.9) 193 (29.3)
otal 456 (100.0) 204 (100.0) 660 (100.0)
*P < 0.01
substances
6,005,004,003,002,001,00
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Table 12: HIV Seroprevalence in MMT at t1 and at 12-Month Follow-Up
2000
t1
2001
t2
Variable Total
n = 660
Total
n = 486
HIV seropositive (N/%) 57 (8.6) 53 (10.9)
HIV negative (N/%) 410 (62.1) 310 (63.8)
Unknown state (N/%) 193 (29.3) 123 (25.3)
Total 660 (100.0) 486 (100.0)
For the hepatitis seroprevalence rates, we had a third of missing values in the
questionnaire. HAV, HBV, and HCV seroprevalence in MMT were high, with a third
with hepatitis A virus, and half of the patients infected with the hepatitis B and
hepatitis C virus (table 13). No significant gender differences were found for HAV,
HBV and HCV). The physicians responsible for the treatment reported, that 7 percent
of the HCV infected patients were enrolled in a medical treatment (interferon
therapy).
At 12-month follow-up we had a decrease in the amount of missing values. This was
due to the sensibilization of the physicians responsible for the MMT of the importance
of this section of the questionnaire for the evaluation of the MMT. The results at
follow-up reflect more realistic prevalence rates. HBV seroprevalence was 55
percent, and HCV seroprevalence was 54 percent (table 13).
Table 13: Hepatitis A, B, and C Seroprevalence in MMT at t1 and t2
Baseline 1 year Baseline 1 year Baseline 1 year
Variable HAV HAV HBV HBV HCV HCV
Positive (N/%) 236 (35.8) 96 (19.8) 309 (46.8) 266 (54.7) 308 (46.7) 260 (53.5)
Negative (N/%) 169 (25.6) 206 (42.4) 131 (19.8) 130 (26.7) 142 (21.5) 128 (26.3)
Unknown state
(N/%)
255 (38.6) 184 (37.8) 220 (33.4) 90 (18.6) 210 (31.8) 98 (20.2)
Total 660 (100.0) 486 (100.0) 660 (100.0) 486 (100.0) 660 (100.0) 486 (100.0)
3.1.4 Reported Drug Use
One section of the questionnaire focussed on the illicit drug use and the doctor asked
the patients, if they had used heroin, cocaine, cannabis, benzodiazepines or alcohol
during the past 30 days prior to interview. According to this section in the ASI, the
doctor had to fill out the number of days: if the patient asked “I take cocaine daily”,
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then he would code [30], if the patient asked “I take cocaine monthly”, then he would
code [01], and so on. Illicit drug use was one of the main treatment outcome
measures for treatment effectiveness.
3.1.4.1 Reported Concomitant Drug Use During the Past 30 Days Prior First
Interview
45 percent of the patients reported they had not used any heroin, and 55 percent
reported they had an illicit heroin use in the past 30 days prior interview. Heroin was
abused on an average of 7 out of 30 days. For cocaine use we found 34 percent with
cocaine use in the past 30 days prior interview on an average of 6 days (table 14).
For cannabis use, we found 56 percent of the patients with cannabis use in the past
30 days prior interview, 56 percent with alcohol use and 16 percent with
benzodiazepine use. There were no significant gender differences in the proportion
of any concomitant drug use, except for cannabis. women reported significantly more
days with cannabis use (ANOVA; F (1,56) = 0.733; P = 0.034). Men reported more
heroin use in the past 30 days than women, but on a non significant level (trend; P =
0.066).
Table 14: Drug Use in the Past 30 Days Prior First Interview (t1)
Drug Male
n=456
Female
n=204
Total
n=660
P-value
Heroin Use:
None (%)
1day or more (%)
mean days (mean, SD)*
CI
42
58
7.0  6
5.96 - 8.00
52
48
6.9  6
5.0 8- 8.81
45
55
7.0  6
6.08 – 7.86
Chi2
0.066
ANOVA
0.971
Cocaine Use:
None (%)
1day or more (%)
mean days (mean, SD)
CI
65
35
5.2  5
3.92 – 6.44
67
33
7.3  7
4.87 – 9.71
66
34
5.8  6
4.66 – 6.91
Chi2
0.361
ANOVA
0.094
Cannabis Use:
None (%)
1day or more (%)
mean days (mean, SD)
CI
44
56
19.3  11
17.57 – 21.03
45
55
22.8  11
19.99 – 25.65
44
56
20.3  11
18.85 – 21.82
Chi2
0.466
ANOVA
0.034
Benzodiazepine Use:
None (%)
1day or more (%)
mean days (mean, SD)
CI
83
17
9.9  10
5.29 – 14.47
86
14
18.7  11
6.70 – 29.62
84
16
11.5  11
7.30 – 15.75
Chi2
0.293
ANOVA
0.098
Alcohol Use:
None (%)
1day or more (%)
mean days (mean, SD)
CI
42
58
17.0  11
15.21 – 18.72
51
49
16.7  11
13.66 – 19.74
44
56
16.9  11
15.39 – 18.40
Chi2
0.095
ANOVA
0.881
Intravenous drug use past 30 days
prior to interview
44 49 45 Chi2
0.149
*Range: 1 – 30 days
As expected, the most common way of using heroin and cocaine was the intravenous
way followed by snorting or smoking these substances. Of the 216 patients which
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reported a heroin use in the past 30 days, 45% said they had applied heroin
intravenously, 27% had snorted and 27% had smoked (table 15). Of the 126 patients
who had used cocaine in the past 30 days, 57% reported they had applied cocaine
intravenously, 22% had snorted and 21% had smoked (table 15). The proportion of
patients using drugs intravenously was higher for cocaine than for heroin.
Table 15: Current Way of Using Substances (Past 30 Days):
heroin cocaine
Intravenous drug use (IDU) (N/%) 96 (45.2) 72 (57.1)
Smoked/ inhalation (N/%) 60 (27.4) 28 (22.2)
Sniff/ snort (N/%) 60 (27.4) 26 (20.7)
Total 216 (100.0) 126 (100.0)
Frequency of Opiate Use During the Past 30 Days for Three Treatment Cohorts:
The 660 patients were divided in three different cohorts to compare the amount of
concomitant opiate and non-opiate use: There were 19 new admissions (up to 0.49
years), 149 average-stay patients  (0.50 – 4.49 years), and 231 long-term patients
(4.5+ years). These three cohorts were compared in drug abuse by time already
spent in treatment. The extent to which drug abuse among these patients decreased
during methadone maintenance treatment is shown in table 16.
As expected, the extent of opiate use among the admission sample was high, with
68.4 percent of concomitant heroin use. 57.1 percent had used cocaine, 46.2 percent
had used cannabis, 76.9 percent had used alcohol, and 7.7 percent sedatives.
Patients in the average-stay sample had a significantly lower prevalence of
concomitant heroin use (62.4%) compared to the admission sample (68.4%). Mean
days of reported heroin use were significantly lower (5.4 days out of 30 days versus
11.5 days out if 30 days) compared to the admission sample (ANOVA, F(1, 105) =
11.247, P = 0.001). Also for cocaine, there was a significant decrease from 57.1
percent (admission sample) to 40.4 percent (average stay sample; P = 0.01), but no
decrease in the mean number of days cocaine was used. There was no decrease in
cannabis, alcohol  and sedative use (table 16).
In the long-term stay sample, compared to the admission and the average-stay
sample, there was a trend for decreased heroin use (Kruskal-Wallis-Test, Chi2 =
5.537, df = 2, P = 0.063) and a significant decrease of cocaine use (Kruskal-Wallis-
Test, Chi2 = 8.895, df = 2, P = 0.012). Thus 48.5 percent reported no use of heroin
and 71.6 percent reported no use of cocaine in the long-term sample. High rates for
alcohol (60.5 percent), cannabis (52.9 percent) and benzodiazepine use (18.6
percent) persisted and remained unchanged (table 16).
Looking at the proportion of patients in the three different cohorts sharing needles
with others, there was a significant decrease over time.
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Table 16: Frequency of Opiate and Non Opiate Drug Use During the Past 30
Days for Three Treatment Cohorts of Methadone Maintenance Patients
Admission sample
(up to 0.49 years)
(n = 19)
Average stay sample
(0.50-4.49 years)
(n = 149)
Long-term sample
(4.5+ years)
(n = 231)
Drug of
abuse
No. % Mean
days
No. % Mean
days
No. % Mean
days
Heroin* 13 68.4 11.5 93 62.4 5.4 119 51.5 7.6
Cocaine 8 57.1 3.5 59 40.4 4.7 59 28.4 7.3
Cannabis 6 46.2 21.3 94 61.0 20.4 117 52.9 20.3
Sedatives 1 7.7 4.0 17 12.3 12.8 40 18.6 12.1
Alcohol 10 76.9 18.9 70 47.0 17.6 133 60.5 16.4
Reduction in prevalence by time in treatment was significant at the 0.001 level for heroin, and at the
0.01 level for cocaine.
3.1.4.2 Reported Concomitant Drug Use at One-Year Follow-Up
Compared to the first interview, the completer-analysis yielded no significant self-
reported increase or decrease of illicit heroin or cocaine use at 12-month follow-up.
However, there was a significant increase in the proportion of patients using
cannabis, non prescribed benzodiazepines and alcohol, but not in the average mean
days they had used it in the past 30 days prior interview (table 17). Thus, MMT had
no impact on the reduction of cannabis, benzodiazepine or alcohol use.
Table 17: Annual Change in Drug Abuse Among MMT Patients (t1 – t2)
Percent of patients
using drug, past 30
days
Percent of patients
using drug, past 30
days
Frequency of use
(Mean days of use
in the past 30 days)
Frequency of use
(Mean days of use
in the past 30 days)
Drug Baseline 1 year Baseline 1 year
Heroin 55.5 52.6 8.0 7.7
Cocaine 34.0 35.0 7.2 6.9
Cannabis 52.9 61.5*** 19.8 20.1
Sedatives 17.0 25.1*** 17.9 18.0
Alcohol 52.2 56.7** 16.5 16.0
McNemar-Test; significantly higher proportion of cannabis-users (P < 0.0001), of benzodiazepine-
users (P < 0.0001); and alcohol-users  (P < 0.001) at 12-month follow-up.
3.1.4.3 Reported Intravenous Drug Use at One-Year Follow-up
At 12-month follow-up, 241 out of 486 patients reported, they had have continued
intravenous drug use in the past six months prior second interview (49.6 percent,
table 18). There was no difference in the proportion of IDUs between the three
treatment cohorts. 168 out of these 241 IDUs reported risk behavior in the past six
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months by sharing needles with others (table 18). The proportion of patients with HIV
risk behavior through needle sharing differed significantly between the three
treatment cohorts (Kruskal-Wallis-Test, Chi2 = 6.505, df = 2, P = 0.039). Thus, the
proportion of needle sharers was significantly lower in the long-term sample (table
18).
Table 18: Frequency of Intravenous Drug Use and Needle Sharing During the
Past Six Months for Three Treatment Cohorts
Admission sample
(up to 0.49 years)
(n = 19)
Average stay sample
(0.50-4.49 years)
(n = 149)
Long-term sample
(4.5+ years)
(n = 231)
Intravenous drug
use, past six
months (%)
50.0 55.5 51.8
Needle sharing,
past six months (%) 42.9 50.0 36.7*
*P < 0.05
Additionally we analyzed changes in lifetime intravenous drug use for patients
enrolled in a MMT. After 12 months, a total of 6.3 percent of the patients who had
never injected (lifetime) had switched from non-intravenous heroin use (smoking,
snorting, sniff) to intravenous drug use. This increase of intravenous drug users was
highly significant (McNemar-Test; Chi2 = 20.833; P < 0.0001) (table 19).
Unfortunately there were no results available from the “new admission cohort”,
because they had terminated their methadone maintenance treatment at 12-month
follow-up and could not be contacted anymore.
Table 19: Annual Change in Intravenous Drug Use, Lifetime (t1 - t2)
Intravenous drug use,
lifetime (%)
Percent of use
change
Group 2000 2001 2000-2001:
Significant
Change
Average stay
sample (%)
75.9 83.0 +7.1
Long-term
sample (%)
79.3 85.1 +5.8
Total 78.1 84.4   +6.3***
***P < 0.0001
3.1.5 Length of Stay in Treatment
The length of stay in treatment is an important measure of patients’ progress in
outpatient MMT and of treatment success: Newly admitted and less motivated
patients tend to leave, those who remain in treatment tend to become rehabilitated
over the years (Ball et al., 1992). Patients’ progress in treatment and rehabilitation is
commonly associated with time in treatment. Thus. The longer patients stay in a
MMTP, the better. The average length of stay in treatment for the total sample at first
interview was 6  4 years (median, 5.4 years; range, 3 months to 25 years). There
were no gender differences concerning the average length of stay in treatment.
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Almost 7% of the 660 patients had been in treatment for one year or less, 7.4 percent
for two years and 8.1 percent for three years. The majority  of the patients (57
percent) had been in MMT for more than five years (Fig. 9).
Figure 9: Length of Stay in Treatment for 660 Methadone Maintenance Patients
3.1.6 Retention in Treatment
At one-year follow-up, 73.6 percent of the patients were still in treatment. The
proportion of patients leaving MMT did not differ between gender (Chi2 = 1.293, df =
1, P = 0.149). The same accounts for different age categories: Younger aged
patients (18 to 29 years) did not drop out of treatment more frequently, than did the
older aged patients (30 to 60 years) (Chi2 = 1.998, df = 1, P = 0.157).
To estimate the survival curve for the total cohort, we calculated a Kaplan-Meier
survival curve (Fig. 10). The outcome of interest was the time to an event. The event
was dropping out of treatment. The mean survival time in MMT for men was 14.6
years (95% CI = 13.2, 16.7), and for women 15.06 years (95% CI = 12.9, 17.2) (log
rank, df = 1, P = 0.989; Fig. 10). As shown in figure 10, most dropouts occurred in the
first years of treatment. The longer the patients are in treatment, the more rarely they
drop out of treatment.
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Figure 10: Survival Analysis of 660 Patients (Kaplan Meier)
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egend: each cross represents the time point of an event, thus one patient dropping out of methadone
aintenance treatment.
.1.7 Methadone Dispensing Practices
uring the regular work week, all three of the clinics dispensed methadone in both
he morning and evening hours. Two of the clinics had two dispensing periods (4
ours a day), and one had one long continuous dispensing period from 7:00 a.m. to
:00 p.m. It should be noted, that the last clinic had an automated dispensing
rocedure. All three clinics were open on Saturdays, and one was open on Sundays.
n general practices, during the regular work week, all dispensed methadone in both
he morning and evening hours. 60 percent of the GP patients received their
edication in the pharmacies.
he dosage policy of methadone maintenance programs are influenced by
ecommendations of federal, state, and local governments, previously established
ispensing practices at each clinic, and knowledge about effective clinical doses.
ispensed daily methadone doses to 639 patients are shown in figure 11. Most
atients, were prescribed doses between 30 mg and 110 mg (68 percent were in this
osage range), 12 percent of the patients received doses below 30 mg, and 20
ercent had doses of 110 mg or higher. The mean methadone dose dispensed to
hese 639 patients was 74.4  47.39 mg (range: 1 mg to 300 mg/d) (Fig. 11).
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Figure 11: Methadone Dose Distribution to 639 Patients
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Fean daily methadone doses differed significantly between the different MMTPs
ANOVA, F(4/634) = 22.771; df = 4, P < 0.0001) (Fig. 12). Patients treated in general
ractice had a mean methadone dose of 68.2  42 mg/d, in pharmacies of 70.5  47
g/d, at clinic1 of 110.9  62 mg/d, at clinic 2 of 82.3  52 mg/d, and at clinic 3 of
4.2  35 mg/d (Fig. 12).
igure 12: Mean Methadone Doses at the Five MMTPs
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The year to year variation in the mean daily methadone dose dispensed at each of
the MMTPs was minimal (74.4  47 mg versus 76.4  51 mg (paired T-Test; T = -
,666; P = 0.506). In detail, these results indicate, that there is a considerable stability
in prescribing practices in specialized clinics and in general practice.
Surprisingly, there were no gender differences in prescribed methadone doses, and
the mean methadone dose was even higher in women. Due to the higher mean
weight of men (73 kg), compared to the lower mean weight of women (61 kg), we
expected a lower methadone dose in women. Adequate methadone doses are
defined by the physicians, looking at the corresponding body weight. The mean dose
prescribed to men was 73.6  45 mg and to women 76.4  52 mg (ANOVA; F(1, 624) =
1012, P = 0.497). This result remained consistent at 12 month follow-up (men, 75.3 
52 mg versus women, 78.7  50 mg; P = 0.450).
Mean methadone doses differed significantly between the three treatment cohorts:
Patients in the admission sample had a prescribed mean methadone dose of 58.1 
23 mg, in the average stay sample of 64.4  41 mg, and in the long-term sample of
80.6  50 mg (ANOVA; F (2,636) = 9.709; P < 0.0001).
Usually, take home medication is allowed by the physician responsible for the MMT
for stabilized patients. Patients with a good compliance, low concomitant drug use
(e.g. heroin, cocaine, alcohol) and good psychosocial functioning can come once a
week to the dispensing site, take one methadone dose orally and take the
methadone medication for six days at home. ‘Take-home’ was defined  as taking the
methadone at home for at least 3 days or more (table 20). 70 percent of all patients
had allowed take-home methadone medication (table 20). For this group the mean
days of take-home medication were 5.9  3 days [95% CI; 5.6 – 6.2]. For 21 percent
of the ‘problematic’ patients, take-home medication was not allowed, or only on
weekends (table 20). Usually the physicians responsible for the MMT allow take-
home medication for stable patients. For unstable patients it would be to dangerous
(e.g. injecting the methadone solution, diversion of methadone, risk of respiratory
depression by taking the methadone with non prescribed benzodiazepines or with
alcohol, access to non tolerant persons).
Table 20: Doses Dispensed On-Site and Take-Home Medication
Total patients
No. %
Dispensed daily on-site* 139 21.1
Take-home, 3 days or more 457 69.2
missing 64 9.7
Total 660 100.0
*except on weekends
The proportion of allowed take-home privileges did not differ between women and
men (80.2% versus 75.1%, P = 0.105). Patients with take-home medication for three
days or more had a significantly lower proportion of any concomitant heroin (55.0%
versus 67.6%, Chi2 = 3.612, df = 1, P = 0.038) and a significantly lower proportion of
any cocaine use (31.2% versus 53.0%, Chi2 = 11.148, df = 1, P = 0.001) compared
to the on-site dispensing sample.
3.1.7.1 Methadone Dose, One-Year Retention and Concomitant Heroin Use
Daily methadone doses  50 mg are known to be more effective than methadone
doses  50 mg (Johnson et al., 1992; Strain et al., 1993). At 12-month follow-up,
patients with more than 50 mg of prescribed methadone had a significantly higher
retention rate (78%) compared to those with less than 50 mg (67.9%) (Chi2 = 8.058;
df = 1; P = 0.003; Fig. 13).
Figure 13: Prescribed Methadone Dose and Retention (n =  484)
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atients receiving less than 50 mg of methadone reported 8.47  7 days with
oncomitant heroin use out of 30 days, patients receiving more than 50 mg of
ethadone reported 6.7  6 days with concomitant heroin use (ANOVA, F (1/245) =
.007, df = 1,  P = 0.084).
.1.8 Comedication
esides the methadone medication, 39.5 percent of all patients (n = 261) received
ther medications like antidepressants, neuroleptics, benzodiazepines due to a
iagnosed comorbidity (Fig. 14). The most frequently prescribed medications were
enzodiazepines (59%), followed by Sedatives (23.7%), antidepressants (21.4%) and
euroleptics (14.9%).
f these 261 patients, 40 percent had two prescribed medications and 15 percent
hree prescribed medications. There was a trend for women to have more prescribed
omediaction (44 percent versus 37.5 percent; Chi2 = 2.582; df = 1; P = 0.064). At 12
onth follow-up we found the same proportion of patients with a comedication (39%)
Fig. 14).
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Figure 14: Prescribed Comedication to 261 Patients42
Multiple responses, n = 401
In the general population there is an estimated number of 13% of subjects with a
current psychiatric disorder (Regier et al., 1190) compared to an estimated number of
47% to 75% of patients in a MMT with a current psychiatric disorder.
Benzodiazepines are more often prescribed for opioid-dependent patients in a MMTP
compared to the general population in Switzerland (8.7%; Ladewig et al., 1996).
3.1.9 Provided consultations to the Patients in 2000 and 2001
The second main purpose of this study was to assess the amount of provided
consultations to each patient. Measurement focused on the frequency of contacts
between physicians and patients within the past six months prior interview. The
frequency of provided consultations was measured at baseline and at 12-month
follow-up. In general, the scheduling of services to patients in MMTPs is organized
around the provision of methadone. Thus, hours of consultations and medical
services are usually coordinated with the dispensing hours for the convenience of
both patients and staff.
The medical staff at the three MMTP and partly in general practice can be divided
into three groups: (1) physicians, psychiatrist; (2) nurse practitioners and physicians’
assistants; and (3) dispensing nurses or pharmacists. At one program (Clinic1) the
actual amount of coverage provided by physicians was 63 hours per week, or 1.5 full-
time equivalent (FTE) for 140 patients. At the second program (Clinic 2) the actual
amount of coverage provided by physicians was 29 hours per week, or 0.7 full-time
equivalent (FTE) for 70 patients. At the clinic 3, there was a 4.8 full-time equivalent
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(FTE) for 480 patients. General practitioners treat an average of three patients in
their general practice.
3.1.9.1 Scheduled and Attended Consultations in the Past Six Months Prior
Interview
The general practitioners and the medical staff at the specialized centres were asked,
how often they scheduled consultations, counseling, or medical sessions in the past
six months prior interview. For this variable, there were only 5% of missings. Overall,
98.2 percent of the patients had at least one offered consultation by their physicians
within six months, and 95.4 percent attended these consultations (table 21). There
were no significant gender differences in the proportion of offered and attended
consultations (table 21). The mean number of scheduled consultations in the past six
months by the physicians were 7.4  5.3 consultations, thus a little more than
monthly sessions (table 21). Patients attended a mean of 6.3  4.9 consultations,
thus approximately one consultations less than scheduled.
Table 21: Scheduled and Attended Consultations to 660 Methadone
Maintenance Patients During the Past Six Months
Variable Male
n =456
Female
n=204
Total
n=660
Offered, none (%)
Offered, one or more consultations (%)
1.8
98.2
1.6
98.4
1.8
98.2
Offered consultations (Mean  SD)
Range
Median
95% CI
7.3  5.4
1 – 41
6.0
6.8 – 7.8
7.5  5.0
1 – 25
6.0
6.8 – 8.2
7.4  5.3
1 – 41
6.0
6.9 – 7.8
Attended, none (%)
Attended one or more consultations (%)
4.4
95.6
5.2
94.8
4.6
95.4
Attended consultations (Mean  SD)
Range
Median
95% CI
6.4  5.1
1 – 40
6.0
5.9 – 6.9
6.2  4.5
1 – 24
6.0
5.6 – 6.9
6.3  4.9
1 – 40
6.0
5.9 – 6.7
3.1.9.2 Scheduled and Attended Consultations Over Time
There was only minimal change over time in the number of scheduled and attended
consultations over time (table 22, table 23). The Wilcoxon-Test revealed an non
significant change over time: First for the sum of scheduled consultations, and
second for the sum of attended consultations. As expected, number of scheduled
consultations showed great variability between the different treatment facilities (table
22).
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Table 22: Annual Change in the Provision of Consultations by Dispensing Site
Offered consultations*
Mean [95% CI]
Change
in year
Percent of patients with one
or more scheduled
consultation
:
Program 2000 2001 2000 2001 %
Change
Clinic 1 11.1 [9.4-12.8] 9.4 [8.2-10.6] -1.7 99.0 100.0 +1.0
Clinic 2 5.6 [3.9-7.2] 4.6 [3.2-6.0] -1.0 100.0 96.7 -3.3
Clinic 3 6.9 [6.5-7.2] 7.0 [6.7-7.3] +0.1 99.0 99.3 +0.3
General
practice
6.9 [5.8-7.9] 6.5 [5.5-7.6] -0.4 95.0 95.3 +0.3
Pharmacies 4.9 [4.0-5.8] 5.5 [4.5-6.4] +0.6 97.7 98.1 +0.4
Total 7.2 [6.8-7.7] 6.9 [6.6-7.3] -0.3 98.2 98.5 +0.3
Table 23: Annual Change in the Attendance of Consultations by Dispensing
Site
Attended consultations*
Mean [95%CI]
Change
in year
Percent of patients with
one or more attended
consultation**
Program 2000 2001 2000 2001 % Change
Clinic 1 8.9 [7.4-10.5] 7.7 [6.6-8.8] -1.2 98.1 100.0 +1.9
Clinic 2 4.5 [3.3-5.7] 3.4 [2.4-4.4] -1.1 97.1 93.3 -3.8
Clinic 3 6.0 [5.7-6.3] 6.0 [5.7-6.3] +0.0 96.3 97.7 +1.4
General
practice
5.4 [4.4-6.5] 5.5 [4.4-6.5] +0.1 93.1 94.2 +1.1
Pharmacies 3.9 [3.0-4.8] 4.4 [3.6-5.3] +0.5 90.9 92.3 +1.4
Total 6.0 [5.6-6.4] 5.8 [5.5-6.1] -0.2 95.4 96.5 +1.1
3.1.9.3 Frequency of Attended Consultations and Treatment Outcome
We were first interested, if there was a association between the number of attended
consultations and main treatment outcome measures (e.g. treatment retention, the
proportion of concomitant heroin use). We expected, that patients with a high amount
of consultations (4 to 7 consultations) would have a higher retention in treatment and
a lower proportion of concomitant opiate drug use, compared to those with less
consultations (0 to 3 consultations).
Overall, major baseline variables (age, gender) and in-treatment variables (e.g.
methadone dose, comedication) did not differ between patients with a high amount of
attended consultations, and  those with a low amount of consultations (table 24). As
to be expected, patients with a high rate of consultations were significantly more
often treated in specialized clinics (P < 0.0001; table 24).
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Table 24: Differences Between Methadone Maintenance Patients with a Low
Rate of Attended Consultations (0 to 3) and a High Rate of Attended
Consultations (4 to 7) During the Past Six Months (n = 616)
Variable 0 to 3
attended
cons.
n=169
4 to 7
attended
cons.
n=447
P-value
Male (N/ %)
Female (N/ %)
111 (65.7)
58 (34.3)
315 (70.5)
132 (29.5)
p = 0.282
Not married
Nationality, Swiss
113 (69.8)
135 (87.7)
328 (74.9)
374 (87.0)
p = 0.431
p = 0.889
Age (years; mean, SD) 35.2  6 34.1  6 p = 0.45
Age at first MMT (years) 28.3  7 28.4  7 p = 0.915
Age at first heroin use (years) 20.3  5 19.1  6 p = 0.514
Treated in General practice (N/ %)
Treated in Specialized clinic (N/ %)
101 (59.8)
68 (40.2)
81 (18.1)
366 (81.9)
p > 0.0001
Retained in Methadone Maintenance
Treatment (%)
61% 81% p < 0.0001
Take-home (only on weekends)
Take-home (3 days or more)
43 (28.7)
107 (71.3)
87 (20.7)
334 (79.3)
p = 0.054
No heroin use past 30 days (N/ %)
Heroin use, at least 1 day (N/ %)
47 (57.3)
35 (42.7)
121 (39.7)
184 (60.3)
p = 0.006
No cocaine use past 30 days (N/ %)
Cocaine use, at least 1 day (N/ %)
63 (81.8)
14 (18.2)
171 (60.9)
110 (39.1)
p = 0.001
No intravenous drug use (N/ %)
Intravenous drug use past 6 months
(N/ %)
61 (62.9)
36 (37.1)
131 (45.5)
157 (54.2)
p = 0.006
Without a comedication (N/ %)
With a comedication (N/ %)
107 (63.3)
62 (36.7)
257 (57.5)
190 (42.5)
p = 0.20
Daily methadone dose (mg/d) 73.7  49 75.6  46 ANOVA
p = 0.66
As we hypothesized, there was a strong association between the amount of attended
consultations and the retention rate. Patients with a higher rate of consultations (4 to
7 consultations) had a significantly better retention rate compared to patients
attending a lower rate of consultations (0 to 3 consultations) (81% versus 61%; Chi2
= 24.53; df = 1; P > 0.0001; table 24; Fig. 15).
The hypothesis of a significant association between a high amount of consultations
and a low amount of concomitant heroin use had to be rejected. Patients with more
consultations (4 to 7 consultations) had significantly more illicit opiate use in the past
30 days (60.3%) than those with less consultations (0 to 3 consultations, 42.7%)
(Chi2 = 8.809; df = 1; P = 0.006; table 24, Fig. 15).
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Figure 15: Number of Attended Consultations, Retention in Treatment and
Concomitant Opiate Drug Use
One-Year Treatment Retention; P < 0.0001
Proportion of concomitant opiate use; P = 0.006
Furthermore, patients with more consultations had significantly more intravenous
drug use in the past six months prior interview (54.2% versus 37.1%; P = 0.006, table
24), and significantly more illicit cocaine use (39.1% versus 18.2%; P = 0.001; table
24). Thus, it seems, that the physicians offer more consultations for the more
‘problematic patients’ with multiple substance use and intravenous drug use. For the
more stabilized patients, they seem to schedule less consultations.
3.1.9.4 Attendance of Consultations as a Measure of Patients’ Cooperation
Secondly, we were interested to analyze the differences between patients with a
“good cooperation” and those with a “unsatisfactory cooperation” with their
physicians. For this purpose we divided the patients into two subgroups with the
following categories: patients with a “good cooperation” (GC) were defined as
patients who attended all scheduled consultations or missed only one consultation;
patients with an “unsatisfactory cooperation” (UC) were defined as patients who
missed more than one scheduled consultation. We analyzed a total of 19 variables, 8
pretreatment patient variables and 11 in-treatment variables (table 25, 26).
The two subgroups differed significantly in 3 out of 4 pretreatment variables: patients
with a “good cooperation” (GC) were more likely to be men, employed and with less
multiple substance use (table 25).
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Table 25: Comparison Between Methadone Maintenance Patients with a “Good
Cooperation” (GC) and Patients with an “Unsatisfactory Cooperation”
(UC) [Patient Variables]
Good
Cooperation
(GC)
n=478
Unsatisfactory
Cooperation
(UC)
n=149
P-value
Male / Female (%) 78.8/ 21.2 70.5/ 29.5 p = 0.024
Age (years) [mean, SD] 34.5  6 34.0  6 p = 0.378
Employed (%) 29.8 14.0 p = 0.002
Multiple substance use at entry in
MMT (mean, SD)
2.7  1 3.6  2 p < 0.0001
Concerning the in-treatment variables, the two subgroups differed significantly in 3
out of 8 in-treatment variables: patients with a “good cooperation” (GC) were more
likely to have less cocaine use in the past 30 days prior interview (P = 0.024), less
contacts to the injection rooms in the past 14 days (P = 0.023), and more take-home
medication allowed (P < 0.0001; table 26). The GC and the UC group did not differ
with regard to treatment retention, prescribed methadone dose, treatment setting and
concomitant heroin use (i.e., the less addicted, the better the compliance or treatment
cooperation).
Table 26: Comparison Between Methadone Maintenance Patients with a “Good
Cooperation” (GC) and Patients with an “Unsatisfactory
Cooperation” (UC) [In-Teatment Variables]
Variable Good
Cooperation
(GC)
n=478
Unsatisfactory
Coop.
(UC)
n=149
P-value
Retained in Methadone
Maintenance Treatment (%)
82 78 p = 0.285
General practice/ Specialized clinic
(%)
75.1 vs. 76.7 24.9 vs. 23.3 p = 0.670
Retained in Methadone
Maintenance Treatment (%)
82 78 p = 0.285
Take-home allowed for (3 days or
more, %)
81.3 60.6 p < 0.0001
Heroin use, 1 day or more in the
past 30 days (%)
6.8 56.6 p = 0.974
Cocaine use, 1 day or more in the
past 30 days (%)
32.0 46.4 p = 0.024
Contacts to the injecting rooms in
the past 14 days prior interview (%)
27.5 38.6 p = 0.023
Daily methadone dose (mg/d) 73.2  46 80.6  51 p = 0.103
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3.1.10 Comparison of Treatment Failures with Those who Remained in MMT
3.1.10.1 Reasons for Leaving MMT
At 12-month follow-up, the practitioners and medical staff noted, if the patients had
left treatment within the past 12 months and why the patients had left methadone
treatment. For this variable we had a high rate of missing values (67%). At follow-up,
171 out of 660 patients had left MMT and the information could be provided only for
74 out of 171 subjects. Consequently, we had to screen the methadone case register
to complete the missing data about the reasons of leaving MMT by March 2001. After
this analysis, 131 out of 171 patients were considered as “treatment failures” and the
remaining 40 patients (23.4 %) were considered as treatment successes or losses
unrelated to the MMT: 16 had withdrawn from opiates, 21 were transferred to another
general practitioner and 3 died of AIDS. Patients which were considered as
“treatment failures” (arrested [n = 6], discharged by program [n = 5], dropped out
voluntarily [n = 26]).
For the majority of the patients (94 patients) the physician responsible for the MMT
had no follow-up information. This fact could be due to the behavior of both, the
patients and the physicians. The Patients do not take contact anymore and the
physicians do not have the time to re-contact their patients. An additional important
result was, that all the 19 patients from the “admission cohort” had dropped out at 12-
month follow-up.
3.1.10.2 Comparison of Treatment Failures With In-Treatment Patients
As outlined in the previous section, treatment failures were considered as losses
related to the MMT. A comparison between the in-treatment cohort and the 131
treatment failures showed significant differences in 4 out of 18 analyzed variables
(table 27). Treatment failures had significantly more prescribed methadone doses
below 50 mg (32.1% versus 22%, Chi2 = 8.058, df = 1, P = 0.003), a significantly
lower rate of allowed take-home medications (64.9% versus 79.5%, Chi2 = 0,557, df
= 1, P = 0.001), a significantly lower rate of prescribed comedication (29.8% versus
42.4%, Chi2 = 6.872, df = 1, P = 0.009), and attended significantly less scheduled
consultations (90.8% versus 96.6%, Chi2 = 7.070, df = 1, P = 0.008) compared to the
in-treatment sample (table 27).
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Table 27: Pretreatment Characteristics of Methadone Maintenance Patients: In-
Treatment versus Treatment Failure Samples
Variables In-treatment at
t2
n = 486
Treatment
Failures
n = 131
Age (mean years, SD) 34.6  6 33.5  7
Gender M/F (%) 67.9 / 32.1 69.6 / 30.4
Age at onset of opiate use (mean years) 19.8  5 19.5  4
Intravenous drug use (lifetime) (%) 79.0 82.0
Age at begin of MMT (mean years, SD) 28.4  6 28.1  7
Duration in current MMT (mean years, SD) 6.2  4 5.4  4
Swiss Nationality (%) 87.8 81.8
Not married (%) 73.2 76.0
Employed (%) 25.5 29.1
Daily Methadone Dose, less than 50 mg  (%) 34.2 49.2**
Mean Methadone dose (mg/d, SD) 76.8  47 69.8  51
Take-home medication, three days or more (%) 79.5 64.9**
With Comedication (%) 42.4 29.8**
Attended one or more consultation in the past 6
months (%)
96.6 90.8**
Intravenous drug use past six months (%) 51.0 58.0
Use of any heroin during past 30 days (%) 58.5 54.7
Use of any cocaine during past 30 days (%) 34.1 35.2
Multi substance use during past 30 days (%) 88.7 92.4
** P < .01
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3.1.10.3 Predictors of Treatment Failure: Cox Regression Analysis
To find predictors of treatment failure, respectively to gain a better understanding of
the process that may be involved in leaving methadone maintenance, we undertook
a forward stepwise regression in which variables representing three kinds of factor
were included as potential predictors of attempts to stop methadone maintenance at
follow-up: baseline demographic variables, attendance of consultations, take-home
privileges, concomitant opiate drug use, methadone dose, dispensing site (table 28).
A forward stepwise multiple regression revealed the following results: Intravenous
drug use in the past six months prior interview (P = 0.009) and a reported cocaine
use in the 30 days prior interview (P = 0.039) predicted leaving treatment at follow-up
(table 29). A similar result was obtained when a backwards stepwise regression was
used. Expected percent of patients remaining in treatment was: 74.1
Table 28: Relative Risks of Treatment Failure, by Patient Characteristics at First
Interview (bivariate associations)
Independent variable RR Sig.
p-value
Sex (Male, female) .038 0.845
Age 1.96 0.161
Intravenous drug use, lifetime 0.10 0.747
Employment status 1.82 0.176
Dispensing site 1.54 0.215
Methadone dose 1.46 0.226
No Take-homes 1.01 0.750
having attended no consultations 1.04 0.747
Intravenous drug use in the past six
months prior interview
14.8 0.001
Heroin use past 30 days 0.82 0.366
Cocaine use past 30 days 2.20 0.138
Having no prescribed comedication 0.99 0.320
Intravenous drug users (in the past 6 months prior interview) were more likely to drop
out of treatment than non intravenous drug users. Cox regression analysis showed a
relative risk (RR) of 2.9. Patients with any cocaine use during past 30 days prior
interview, show a relative risk of 2.6 to drop out of treatment compared to patients
without concomitant cocaine use (table 29). Thus. The less addicted the patients the
more likely a methadone maintenance treatment will be successful.
Table 29: Final Model from Forward Stepwise Regression of Predictors of
Leaving MMT (n = 616)
Variable Odds ratio Significance
Intravenous drug use in the past six
months prior first interview
2.89 P = 0.009
Any cocaine use during last 30 days
prior first interview
2.66 P = 0.039
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3.2 TREATMENT OUTCOMES IN GENERAL PRACTICE AND IN SPECIALIST CLINIC SETTINGS
After it had been found that the three methadone maintenance programs and the
general practices were effective in markedly reducing intravenous drug use, and
other deviant behavior among patients who remained in treatment, the question
arose if the 200 patients treated in general practice had similar or even better
outcomes than the 460 patients treated in specialized clinics ?
In 2000 in the city of Basel, approximately 674 physicians worked in private practice
(BFS, T 14.2.2.3). A total of 120 physicians were providing office-based methadone
maintenance treatment (MMT), thus 18 percent of all private practitioners.
In this cohort study a total of 70 private practitioners (GP) participated and each had
an average of 3 patients in his practice (range: 1 to 33). Looking at the specialty of
the physicians, we found a third of GPs, a third in internal medicine and a third of
psychiatrists. For 32% of the patients with office-based MMT, the dispensing site for
the methadone was a pharmacy, whereas the GP regularly sees the patient in his
practice for consultations.
3.2.1 Comparison of Patient Characteristics in General Practice versus in
Specialized Clinics
The sociodemographic characteristics of the two treatment groups differed in 2 out of
7 variables (table 30). Patients treated in general practice (GP) were significantly
older (35.8  6 years versus 33.8  6 years; T-test; T(1,659) = 3.702, P < 0.001), and
had a significantly lower proportion with an employment (18.3% versus 29.0%; Chi2 =
5.570, df = 1, P = 0.018) compared to the patients in specialized clinics (SC). There
were no significant differences between groups in gender, in marital status, in
parenthood, in nationality or education (table 30).
Table 30: Comparison of Demographic Patient Characteristics in General
Practice versus in Specialized Clinics (t1)
Variable General
practice
n=200
Specialized
clinics
n=460
Total
Sample
n=660
Age (years) (Mean  SD)
Range
Median
95% CI
35.8  6***
21 – 55
36.02
34.9 – 36.7
33.8  6
20 – 59
32.80
33.2 – 34.4
34.4  6
20 – 59
33.75
33.9 – 34.9
Sex, M (%) 69.0 69.0 69.0
Marital status:
Unmarried (%)
Married (%)
Divorced/ separated (%)
76.7
8.0
15.3
73.7
9.7
16.6
74.6
9.1
16.3
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Parenthood:
With child (%)
Without child (%)
27.0
73.0
30.0
70.0
29.8
70.8
Nationality:
Swiss (%)
European Union and other countries (%)
90.6
9.4
85.4
14.6
86.9
13.1
Education:
School absolved (%)
Apprentice (%)
Higher degree school/ University (%)
45.2
46.8
8.0
46.2
52.2
1.6
45.9
50.7
3.4
Employment history:
Employed (%) 26.6* 31.1 29.8
* P < .05; *** P < .001
3.2.2 Comparison of Drug Use Histories
There were no significant differences in drug-use history between the GP and the
clinic samples, except for age at first alcohol use and multiple substance use (table
31). Patients treated in GP started alcohol use at a significantly older age (16.8  6
years versus 15.0  3 years; T-Test, T(1,207) = 2.341, P = 0.020), and had a
significantly lower rate of multiple substance use (75% versus 93%; Mann-Whitney-
Test, Z = -6.853, P < 0.001) than the clinic sample. The prevalence rate of patients
with intravenous drug use (IDU) did not differ between groups. Patients in both
groups entered MMT at an average age of 28 years (table 31).
Tab. 31: Drug Use History, Patients in General Practice versus in Specialized
Clinics (t1)
Variable General
practice
n=200
Specialized
clinics
n=460
Total
Sample
n=660
Age at admission to methadone
maintenance treatment (mean, SD)
Range
95% CI
28.2  6
16 – 50
27.4 – 29.1
28.5  6.8
16 – 54
27.8 – 29.1
28.4  6.6
16 – 54
27.9 – 28.9
Age at first heroin use (mean, SD)
95% CI
19.1  4
18.3 – 20.0
19.8  5
19.3 – 20.3
19.7  5
19.2 – 20.1
Age at first cocaine use (mean, SD)
95% CI
21.5  5
20.1 – 22.8
21.3  5
20.7 – 21.9
21.3  5
20.8 – 21.8
Age at first cannabis use (mean, SD)
95% CI
15.6  2
14.5 - 16.8
15.6  3
15.2 - 16
15.6  3
15.2 – 15.9
Age at first alcohol use (mean, SD)
95% CI
16.8  6*
13.9 – 19.7
15.0  3
14.6 – 15.4
15.1  3
14.7 – 15.6
Age at first benzodiazepine use
(mean, SD)
95% CI
22.5  4
19.8 – 25.1
22.7  6
21.7 – 23.7
22.7  6
21.7 – 23.6
Proportion of patients with multiple
substance use (%)
75.0*** 93.0 89.0
Proportion of patients with
intravenous drug use (lifetime) (%)
80.0 76.0 77.2
* P < .05; *** P < .001
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3.2.3 Comparison of the Somatic Health State
One section of the questionnaire asked questions about infectious diseases like HIV
seropositivity, hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus
(HCV). A third of the physicians did not fill out this part of the questionnaire or wrote
“unknown HIV state” and “unknown “hepatitis state” in the first interview. Missing
rates had decreased at one-year follow-up  interview due to an intervention of the
health authorities, by directing the physicians’ attention to the importance of this
section of the questionnaire for the evaluation of the MMT. Thus, the results at follow-
up reflect more realistic prevalence rates.
The prevalence rate of HIV seropositivity did not differ significantly between office-
based MMT and MMT in specialized clinics (8.2 versus 11 percent; Chi2 = 4.119, df =
1, P = 0.128; table 32). The same accounts at 12-month follow-up. As outlined
before, the increase of the prevalence rates over time is biased, due to a greater
number of physicians, completing this section of the questionnaire.
Table 32: HIV Seroprevalence in General Practice versus Specialized Clinics at
t1 and at One-Year Follow-Up
Baseline (t1) 1 year (t2)
Variable General
practice
n=200
Specialized
clinics
n=460
General
practice
n=200
Specialized
clinics
n=460
HIV seropositive (%) 8.2 11.0 12.3 15.2
HIV negative (%) 62.0 61.0 81.2 81.7
Unknown state (%) 29.8 28.0 6.5 3.1
Total 100.0 100.0 100.0 100.0
Comparing HAV, HBV, and HCV seroprevalence rates in patients treated in GP
versus in specialized clinics, the analysis revealed a significantly higher proportion of
patients infected with the hepatitis A virus (Chi2 = 14.666, df = 1, P < 0.0001) and
with hepatitis B  (Chi2 = 8.735, df = 1, P = 0.003) in the clinic sample. Hepatitis C
seroprevalence did not differ between groups (table 33).
Table 33: Hepatitis A, B, C Seroprevalence in MMT (t1)
Variable General  practice Specialized clinics
Hepatitis HAV HBV HCV HAV HBV HCV
Positive (%) 22.3 50.0 54.6 33.8*** 64.0** 66.0
Negative (%) 57.7 40.0 25.4 36.2 25.7 24.0
Unknown state (%) 20.0 10.0 20.0 30.0 10.0 10.0
Total 100.0 100.0 100.0 100.0 100.0 100.0
** P < .01; *** P < .001
At 12-month follow-up we had a decrease in the amount of missing values. Thus, the
results at follow-up reflect more realistic prevalence rates. Patients treated in
specialized clinics had significantly higher proportions of HAV, HBV and HCV
prevalence rates (P < .05; table 34).
Table 34: Hepatitis A, B, C Seroprevalence in MMT at 12-month follow-up (t2)
Variable General  practice Specialized clinics
Hepatitis HAV HBV HCV HAV HBV HCV
Positive (%) 22.1 52.6 51.3 28.5* 65.1* 65.3*
Negative (%) 55.2 35.1 32.2 57.3 26.8 27.1
Unknown state (%) 22.8 12.3 16.4 14.2 8.1 7.6
Total 100.0 100.0 100.0 100.0 100.0 100.0
* P < .05
3.2.4 Comparison of Methadone Dispensing Practices
There were no statistically significant difference in the main daily doses of methadone
prescribed to the patients by the GPs (69.3  44.7 mg), and in the clinics (76.7  48.4
mg) at first interview, but a trend (P = 0.068). At 12-month follow-up, the mean daily
doses of methadone prescribed to the patients by the GPs (68.6  46.3 mg) was
significantly lower compared to the methadone doses prescribed by specialized
clinics (79.6  52.4 mg; ANOVA; F(1,645) = 6.348;  P = 0.012; Fig. 16).
Figure 16: Prescribed Mean Methadone Doses by the GPs and the Clinics54
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There were no statistically significant difference in the proportion of low doses of
methadone prescribed to the patients by the GPs (39.5%), and in the clinics (37.2%).
To measure methadone dose changes over time, we carried out a repeated
measures analysis of variance with the study completers. There was a significant
effect over time (ANOVA; F(1,621) = 18.914; P < 0.001) and a significant interaction
(ANOVA; F(1,621) = 18.914; P < 0.009). Thus, methadone doses prescribed by GPs
decreased significantly over time, whereas methadone doses prescribed by clinics
increased significantly over time.
There were no significant differences between the general practices and the clinics in
the proportion of allowed take-home medication (GPs group 69.0 versus specialized
clinics 69.3%) (table 35). Considering the higher proportion of patients with
concomitant drug use in the clinic sample, we expected a lower rate of take-home
privileges in this group. Patients with a prescribed comedication did not differ
between groups (table 35).
Table 35: Methadone Doses Dispensed On-Site and as a Take-Home Medication
General practice Specialized clinics
No. % No. %
Dispensed daily on-site* 43 21.5 96 20.9
Take-home, 3 days or more 138 69.0 319 69.3
With comedication 83 42.1 172 37.4
*except on weekends
3.2.5 Treatment Retention in General Practice versus in Specialized Clinics
At one-year follow-up, 75.6% of the GP patients and 72.2% of the clinic patients were
still in their treatment (Chi2 = 0.842, df = 1, P = 0.359). Thus, the one-year retention
rate did not differ between groups. The reasons for leaving treatment were shown in
chapter 3.9. A Cox regression procedure was used to compare retention times
controlling for baseline differences between the populations.
To compare the survival experience of the two groups of patients, we calculated the
Kaplan-Meier survival curves separately for each group (Fig. 17). The mean survival
time for patients treated by GPs was 17 years (95% CI = 14.8, 18.9), and 13.2 years
(95% CI = 11.8, 14.6) for clinic patients. Log rank testing of the survival curves
revealed a significantly better retention for patients in general practices (Log rank test
= 14.18, df = 1, P = 0.0002; Fig.17). Thus, the survival probability (remaining in
treatment) of a patient treated by a GP was significantly higher, than for a patient
treated by a specialized clinic.
Figure 17: Survival Analysis of  Patients treated by GPs and in Clinics
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egend: The survival time was significantly longer for patients treated in general practice (Kaplan
eier survival analysis, log rank-test, P = 0.0002). A cross (+) represents the time point, when a
atient treated by a GP is dropping out of MMT; a delta () represents the time point, when a patient
reated by a clinic is dropping out of MMT.
.2.6 Reported Concomitant Drug Use During the Past 30 Days Prior to the First
nterview for Patients treated by GPs an in Clinics
s outlined in chapter 3.1.4, patients were asked by their physician responsible for
he treatment, if they had used heroin, cocaine, cannabis, benzodiazepines or
lcohol during the past 30 days prior to the first interview. Concomitant drug use is
ne of the main treatment outcome measures for MMT effectiveness.
e first carried out an intention-to-treat analysis (ITT-analysis, all patients enrolled in
he study, including drop outs), and secondly a completer analysis (only the patients
till in treatment at 12-month follow-up).
he intention-to-treat analysis yielded the following results: In the GP group a
ignificantly higher proportion of patients (46 percent) reported they had not used any
eroin in the past 30 days prior first interview compared to 26 percent in the patients
reated in specialized clinics (Chi2 = 21.056, df =1, P < 0.0001; table 36). For cocaine
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use we found again, a significantly higher proportion without any cocaine use in the
GP group (79 percent versus 59 percent; Chi2 = 14.631, df =1, P < 0.0001).
Patients were also asked if they had used drug intravenously in the past 6 month
prior to the first interview: a significantly lower proportion of patients treated by GPs
reported intravenous drug use compared to the clinic sample (37 percent in versus
58 percent; Chi2 = 16.083, df =1, P < 0.0001; table 36).
Table 36: Reported Drug Use at First Interview, Patients treated by GPs versus
Specialized Clinics (ITT-analysis) a
First Interview (t1)
Drug General
practice
n=200
Specialized
clinics
n=460
P-value
Heroin use:
None (%)
1day or more (%)
mean days (mean, SD)
95% CI
46
54
6.9  6
5.10 – 8.78
26
74
7.4  6
6.47 – 8.37
Chi2
p < 0.0001
ANOVA
0.629
Cocaine use:
None (%)
1day or more (%)
mean days (mean, SD)
95% CI
79
21
5.3  5
3.23 – 7.42
59
41
5.7  5
4.73 – 6.81
Chi2
p < 0.0001
ANOVA
0.694
Cannabis use:
None (%)
1day or more (%)
mean days (mean, SD)
95% CI
50
50
20.9  11
18.17 – 23.66
42
58
20.1  11
18.35 – 21.92
Chi2
p = 0.156
ANOVA
0.641
Benzodiazepine use:
None (%)
1day or more (%)
mean days (mean, SD)
95% CI
81
19
11.4  10
7.20 – 15.70
86
14
14.3  11
11.66 – 17.70
Chi2
p = 0.238
ANOVA
0.395
Alcohol use:
None (%)
1day or more (%)
mean days (mean, SD)
95% CI
42
58
17.6  11
15.01 – 20.25
46
54
16.7  11
14.77 – 18.53
Chi2
p = 0.510
ANOVA
0.550
Intravenous drug use past
6 months prior to the first
interview (%)
37 58
Chi2
p < 0.0001
a Intention-to treat analysis
The completer analysis yielded similar results as the previous ITT-analysis: In the GP
group a significantly higher proportion of patients reported they had not used any
heroin and cocaine in the past 30 days prior first interview compared to the patients
treated in specialized clinics. The same accounts for the proportion of intravenous
drug use (table 37).
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Table 37: Reported Drug Use at First Interview, Patients treated by GPs versus
Specialized Clinics (COMPLETER-ANALYSIS)
First Interview (t1) a
Drug General
practice
n=114
Specialized
clinics
n=244
P-value
Heroin use:
None (%)
At least 1day or more (%)
mean days (mean, SD)
51
49
8.4  6
28
72
7.4  6
Chi2
p < 0.0001
n.s.
Cocaine use:
None (%)
At least 1day or more (%)
mean days (mean, SD)
76
24
4.7  4
59
41
6.7  6
Chi2
p = 0.001
n.s.
Cannabis use:
None (%)
At least 1day or more (%)
52
48
44
56
Chi2
p = 0.254
Benzodiazepine use:
None (%)
At least 1day or more (%)
82
18
85
15
Chi2
p = 0.601
Alcohol use:
None (%)
At least 1day or more (%)
43
57
50
50
Chi2
p = 0.259
Intravenous drug use past 6
months prior to the first
interview (%)
40 58
Chi2
p = 0.009
a Completer analysis
3.2.6.1 Concomitant Heroin Use Over Time: Completer Analysis
Proportions of concomitant heroin use over time were analyzed for study completers.
The results from self-reported heroin use at one-year follow-up are displayed in figure
18. For patients remaining in MMT, the percentage of any self-reported heroin use
(during the last 30 days) throughout the study differed significantly between groups
with 49% in the general practice group and 72% in the specialized clinics group (Chi2
= 17.808; df = 1; P < 0.0001), and with 53% versus 78% at the second interview
(Chi2 = 23.018; df = 1; P < 0.0001; Fig.18). The proportion of self-reported heroin use
increased over time in both groups: on a significant level for patients treated in
specialized clinics (72% to 78%; Wilcoxon-Test; Z = -2.121; P = 0.034) and on a non-
significant level for patients treated in general practice (49% to 53%; Wilcoxon-Test;
Z = -,784; P = 0.433).
Furthermore, frequencies of concomitant heroin use over time were analyzed for
study completers. At first interview, mean days of heroin use of 8.4  6 days were
reported in the general practice group and of 7.4  6 days in the clinic sample
respectively (1 to 30 days). At 12-month follow-up, mean days of heroin use of 9.7 
7 days were reported in the general practice group and of 7.6  6 days in the clinic
sample respectively. The two groups did not differ in the frequency of heroin use
(mean days of heroin use in the past 30 days) (ANOVA; F(1,212) = 2.755; p = 0.098). A
repeated measures of variance revealed no significant increase of concomitant
heroin use over time (F(1, 424) = ,242; p = 0.623). A covariate analysis of age and
length in treatment revealed that these variables had no impact on the results.
Figure 18: Heroin Use at t2, Completer Analysis
L
(
3
T
f
p
s
c
4
o
a
F
s
r
t
f
g
p59
egend: a significant higher proportion of heroin use in patients treated in specialized clinics
Chi2 = 23.018; df = 1, p < 0.0001)
.2.6.2 Concomitant Cocaine Use Over Time: Completer Analysis
he results from self-reported cocaine use at one-year follow-up are displayed in
igure 19. For patients remaining in methadone maintenance treatment, the
ercentage of any self-reported cocaine use (during the past 30 days) throughout the
tudy differed significantly between groups with 24% in the GP group and 41% in the
linic group (Chi2 = 10.608; df = 1; P = 0.001) at first interview, and with 26% versus
2% at the second interview (Chi2 = 8.410; df = 1; P= 0.004; Fig. 19). The proportion
f self-reported cocaine use remained stable over time in both groups and
ccordingly there was no effect over time (P = 0.593; P = 0.655).
urthermore, frequencies of concomitant cocaine use over time were analyzed for
tudy completers. At first interview, mean days of cocaine use of 4.7  4 days were
eported in the general practice group and of 6.7  6 days in the clinic sample (during
he past 30 days). The two groups did not differ in the frequency of cocaine use at
irst interview (ANOVA; F(1,129) = 1.922; P = 0.168), and at 12-month follow-up (GP
roup, 7.8  7 days; SC group, 7.1  6 days; ANOVA, F(1, 252) = 2.660; P = 0.105). For
atients treated in general practice, there was a significant increase of cocaine use
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over time (ANOVArm; F(1, 252) = 4.499; P = 0.036). A covariate analysis of age and
length in treatment revealed that these variables had no impact on these results.
Figure 19: Cocaine Use at t2, Completer Analysis
Legend: a significant higher proportion of cocaine use in patients treated in specialized clinics
Chi2 = 11.975; df = 1, P < 0.001
3.2.7 Comparison of Scheduled and Attended Consultations in General
Practice versus in Specialized Clinics
At first and second interview, the physicians responsible for the MMT had to report
the number of scheduled consultations and the number of attended consultation by
the patient in the past six months.
3.2.7.1 Comparison of Attended Consultations, ITT- Analysis
At first interview, patients in general practice attended an average of 5.15 out of 6.19
scheduled consultations, patients in specialized clinics attended an average of 6.80
out of 7.86 scheduled consultations in a six-months period (table 38). This means,
that patients in both groups attended approximately one consultation less than
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scheduled by their physicians. As expected, patients in specialized clinics had
significantly more scheduled consultations, and as a consequence, attended
significantly more consultations (table 38). These results were similar at  follow-up
(table 38).
Tab. 38: Scheduled and Attended Consultations, Patients treated by GPs
versus Specialized Clinics at First Interview and at One-Year
Follow-Up (t1-t2)
Variable General
practice
n=182
Specialized
clinics
n=434
Total
Sample
n=616
P-value
Number of scheduled consultations in
the past 6 months (Mean  SD) at t1
Range
95% CI
6.19  5
1 – 26
5.46 – 6.97
7.86  5
1 – 41
7.35 – 8.36
7.37  5
1 – 41
6.95 – 7.78
ANOVA
P < 0.0001
Number of scheduled consultations in
the past 6 months (Mean  SD) at t2
Range
95% CI
6.14  5
1 – 29
5.42 – 6.87
7.42  4
1 – 30
7.04 – 7.80
7.04  4
1 – 30
6.70 – 7.39
ANOVA
P < 0.001
Number of attended consultations in
the past 6 months (Mean  SD) at t1
Range
95% CI
5.15  5.88
1 – 25
4.41 – 6.97
6.80  5
1 – 40
6.34 – 7.27
6.32  5
1 – 40
5.93 – 6.71
ANOVA
P < 0.0001
Number of attended consultations in
the past 6 months (Mean  SD) at t2
Range
95% CI
5.25  5
1 - 23
4.55 – 5.95
6.28  4
1 – 30
5.94 – 6.61
5.98  4
1 – 30
5.67 – 6.30
ANOVA
P < 0.004
3.2.7.2 Comparison of Attended Consultations Over Time: Completer Analysis
Frequencies of attended consultations over time were analyzed for study completers.
At first interview, the mean number of attended consultations reported in the GP
group were 4.7  4 consultations and 6.6  4 consultations in the clinic sample
(range: 1 to 30 consultations). At 12-month follow-up, the mean number of attended
consultations reported in the GP group were 6.4  5 consultations and 6.1  4 in the
specialized clinics group respectively. The two groups differed significantly in the
frequency of attended consultations (ANOVA; F(1,538) = 8.369; P = 0.004). As shown
in the ITT-Analysis, this was due to more offered consultations in specialized clinics.
A repeated measures of variance revealed a significant increase of consultations in
the GP group over time (ANOVA; F(1,538) = 14.13; P < 0.0001). A covariate analysis of
patients’ age and length in treatment revealed that these variables had no impact on
the results.
3.2.7.3 Frequency of Attended Consultations and Treatment Outcome
Additionally, we analyzed the proportion of patients attending a low rate (0 to 3
consultations) and a high rate (4 to 7 consultations) in each treatment setting (see
chapter 3.1.9.3). Specialized clinics had a significantly higher proportion of patients
attending a high rate of consultations compared to general practices (83% versus
49%; Chi2 = 76.737; df = 1, P < 0.0001). The ratio for patients attending a low rate of
consultations was 51% for the GP group versus 17% for the clinic sample.
As shown for the total sample in chapter 3.1.9.3, there was a strong association
between the number or attended consultations and retention in treatment. For
patients treated in general practice, there was a strong association between the
amount of attended consultations and retention in treatment. Patients with a high rate
of consultations had a significantly better retention rate (86%) compared to patients
attending a low rate of consultations (66%) (Chi2 = 9.977; df = 1; P = 0.002) (Fig. 21).
This result was also consistent for patients treated in specialized clinics (78.7%
versus 54.2%; Chi2 = 19.019; df = 1; P < 0.0001) (Fig. 20).
The hypothesis of an association between a high rate of consultations and a low rate
of concomitant heroin use could be demonstrated, but only for patients treated in
general practice (Fig. 20). Patients with a high rate of consultations had a significantly
lower rate of concomitant heroin use (29.4%) compared to patients attending a low
rate of consultations (41.8%), but this difference was not significant  (P = 0.133) (Fig.
20). Thus, for the GP group, the amount of consultations probably do not have an
impact on concomitant heroin use.
For the clinic sample an association between a high rate of consultations and the
proportion of concomitant heroin use could be demonstrated, but in an inverse way.
Patients with a high rate of consultations had a significantly higher proportion of
concomitant heroin use  (61.5%) compared to those with a low rate of consultations
(35.6%) (Chi2 = 10.776; df = 1; P = 0.001) (Fig. 21). Thus, for the clinic sample,
patients with concomitant drug use seem to get more treatment contacts and
treatment services, than patients with no or less concomitant heroin use.
Figure 20: Number of Attended Consultations, Retention in Treatment and
Concomitant Opiate Use in General Practice
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Figure 21: Number of Attended Consultations, Retention in Treatment and
Concomitant Opiate Use in Specialist Clinic Settings.
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4. Discussion
4.1 Treatment Outcomes of the Total Sample
To our knowledge, this is the first large-scale study comparing treatment outcomes of
methadone maintained patients in general practice versus in specialized clinics in
terms of psychosocial support. The first part of the discussion focus on the results of
treatment outcomes in the total sample (n = 660), the second part focus on the
comparisons between patients treated in general practice and in specialist clinic
settings.
There were no significant baseline gender differences, except for women with a
younger age when entering a MMT and a higher proportion of married women
compared to men. The overall mean age was 34.4 years with 69% of men. The result
of less patients from minority groups in MMT (13%) than in the general population in
the city of Basel (27.7%) indicates, that more efforts are needed to attract these
groups of opioid dependent subjects in addiction treatments. Furthermore efforts for
the amelioration of the formal education, apprentice, and higher degree school of
addicted patients must be undertaken, as well as an increase of the proportion of
patients with an employment. This worser formal education and employment status of
opioid dependent subjects compared to the general population could also be
demonstrated in the methadone treatment outcome studies of Hermann (1986), and
Petitjean & Schaller (2002b).
The mean age at first heroin and cocaine use is comparable to earlier findings of
MMT outcome studies in Basel (Petitjean et al., 2000), in Geneva (Petitjean &
Schaller, 2002 b), and in the United States (Ball & Ross, 1991, p. 41). The high rate of
multiple substance use before entering a MMT of 89% is consistent with a recently
published study of Gossop et al. (2003), who reanalyzed the baseline characteristics
of 1075 methadone maintained patients in the UK and found 87% of patients with
prior multiple substance use. These pre-treatment characteristics are very important
and until now, they have not been considered in the whole literature of the
effectiveness of MMT, which are all predicting on one substance, heroin.  Thus, these
results should be considered in new clinical interventions, in future clinical studies
and in the interpretation of treatment outcomes.
The prevalence rates of HIV seropositivity between 9% (at t1) and 11% (at t2) are
within the expected range of previous studies in Basel (Petitjean et al., 2000) and the
statistics of the federal public health authorities (BAG, Aids und HIV in der Schweiz,
2000). Maintenance treatments in other cantons in Switzerland, like Vaud (B. Favrat,
2001) reported a HIV prevalence rate of 9% in 1040 methadone maintained patients;
in Geneva a HIV prevalence rate of 11.5% was reported in 2000, respectively 13.2%
in 2001 (Petitjean & Schaller, 2002b). In the present study, we found significantly
higher rates of HIV seropositivity  in women. This is consistent with the results of a
recently published study of Morrow & Costello (2004). They developed a targeted
prevention program for women and emphasized the importance of such interventions
in daily clinical practice. Furthermore, the high proportion of patients with a retroviral
medication could be explained by a high engagement of internists in hospitals
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(treatment and research) for this subgroup of patients (Opravil et al., 2002).
Observing the HIV prevalence rates in MMT in the City of Basel and the number of
MMTs over time, we can see a significant decrease of HIV infected patients and an
increase of MMTs over the last decade.
Looking at the prevalence rates of hepatitis A (36%), B (55%)  and C (54%), we
found similar rates as reported in earlier MMT evaluation studies (Petitjean et al.,
2000; Petitjean & Schaller, 2002b). Due to the 30% of missing values, the results
must be interpreted with caution because of possible under representation. Cullen
and colleagues (2003) identified in a GP sample (n = 380) in Ireland, 73% of the
MMT patients  being HCV positive. Fitzgerald and colleagues (2001) found in 138
client records a 79% having antibodies to hepatitis C and 16.37% were HIV positive.
Retention in treatment: compared to earlier large-scale observational studies, where
the authors found an overall retention rate between 63.5 percent (Ball & Ross,1991),
respectively 65 percent (Hubbard et al., 1989) and 90 percent (Gearing et al., 1974),
the one-year retention rate of 74 percent in this cohort study can be judged as very
good. Furthermore the results show that 78% of the patients are in MMT for more
than 3 years, demonstrating the effectiveness of these treatments and the capacity to
retain opiate-dependent patients in treatment. Consistent with the results from
previous RCTs’ and observational studies (Ball & Ross, 1991; Payte et al., 1993; Eap
et al., 2000; McGlothlin et al., 1981a; Joe et al., 1991; Caplehorn et al., 1994),
patients receiving over 50 mg of methadone in our study, had a significantly longer
length of stay in treatment compared to those receiving less than 50 mg daily, and a
significantly better retention in treatment rate.
Methadone dispensing practices: Most patients were prescribed methadone doses
between 30 mg and 110 mg, thus 68% were in this dose range. The mean daily
methadone dose of 74 mg indicates, that most patients are in a good clinically
recommended dosage range. Surprisingly, we found even higher mean methadone
dosages in women. Looking at the lower weight of women we would expect lower
methadone doses, corresponding to the body weight. This gender specific result
should be explored in future clinical trials, due to a lack of existing gender
comparison studies. The proportion of 70% of the patients with allowed take-home
methadone medications can be interpreted on one hand as a ‘laisser faire’ policy of
the physicians, or on the other hand as a high proportion of ‘unproblematic patients’
having matched (according to patients needs) treatment modalities. The evidence,
that patients with take-home privileges have a significantly lower proportion of
patients with concomitant heroin and cocaine use do support this hypothesis. One
can be confident, that the physician have a good judgement. Prescribed
comedication in 40% of the patients indicates, that nearly a half of the patients have
a co-occuring disorder (somatic disorder, one or more psychiatric disorders, one or
more disorders related to other substance use). This is bellow known prevalence
rates from previous studies (Table 3, p. 7).
Reduction in opioid use is one of the main treatment outcome variables to measure
the effectiveness of MMT: As expected, the comparison of the three treatment
cohorts (admission sample 68% concomitant heroin use; average-stay sample 62%,
long-term sample 52%) clearly showed a significant reduction of opioid use in MMT
over time. But the reduction was not as impressive as the results reported from the
multi-site study of Ball & Ross, where the concomitant opioid use decreased from
66.7% to 7.6% (Ball & Ross, 1991, p. 164).
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Proportion of patients (n = 660) without opioid use: the proportion of patients without
any heroin use in the past 30 days prior interview was 45 percent. This results are
not as good as the results reported in the meta-analysis of Marsch (1998), which
found an overall proportion of patients without opioid use of 67 percent, as well as
Vanichseni (72%; 1991) and Yancovitz (71%; 1991). On the other hand, Ball & Ross
(1991) could demonstrate that there was a considerable variation of abstinent
patients from one program to another (range: 44% to 90%). Our results do not
support the evidence of an association between high methadone doses (more than
50 mg) and less concomitant heroin use, as was found by Gossop et al. (2003),
Hartel  et al. (1995), Johnson et al. (1992, Stohler et al. (1998), Strain et al. (1999),
and Preston et al. (2000).
Reduction in cocaine use:  Furthermore, a significant reduction of cocaine use could
be observed in the three treatment cohorts (admission sample 57%; average-stay
sample 40%, long-term sample 28%) over time. This is consistent with the results
from Magura et al. (2002), indicating that MMT can help dually-addicted patients to
reduce their cocaine use.
Evidence was found, that the MMT had no impact on the reduction of concomitant
use of cannabis, sedatives and alcohol, thus there was even an increase over time
for these substances. These results are consistent with the results from Ball & Ross
(1991) and Gossop (2003). This result should be of concern for the physicians
responsible for the MMT, and patients should be instructed about the risks of a
respiratory depression by taking methadone and alcohol together, as well as their
alcohol use could be controlled by breath tests.
Intravenous drug use: Surprisingly, there was an significant increase of lifetime
intravenous drug use in the cohorts (average-stay sample from 76% to 83%; long-
term sample from 79% to 85%), representing 6% of the non IDUs’ switching to
intravenous drug use within one year. One possible explanation could be an increase
of cocaine dependent patients, due to an increase of available cocaine in European
countries, or “heroin chasers” switching from smoking to intravenous heroin use.
These findings should be of concern for the clinicians treating opioid-dependent
patients in MMT. However, the evaluation showed a significant decrease of needle
sharing over time, indicating a decrease of risk behavior in the cohort.
Offered number of consultations and treatment outcome in the total sample: A
second research question hypothesized that patients with more scheduled
consultations would have better treatment outcomes, than those with less scheduled
consultations. Our findings are consistent with previous studies, demonstrating that
patients with more consultations had a significantly better retention in treatment (81%
versus 61%) compared to patients with less scheduled consultations. Thus,
demonstrating that the H1-hypothesis is true. This result is consistent with the
findings of McLellan et al. (1988, 1993) and Joe et al. (1991), demonstrating that the
“dose” of treatment services can determine treatment outcomes: In the study of
McLellan (1993), patients with methadone dispensing alone had a 6-month retention
rate of 31%, those with methadone + standard counseling a retention rate of 59%,
and those with methadone + enhanced counseling (counseling, medical/ psychiatric,
employment, and family therapy) had a retention rate of 81%. An association
between amount of counseling and improved outcomes has been reported in several
other studies (Ethridge et al., 1995; Fiorentine & Anglin, 1996).
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An association between a high amount of consultations and less concomitant heroin
use was not found and the hypothesis H1 has to be rejected for this outcome
measure. Our results showed, that patients with less consultations had significantly
less concomitant drug use, those with more consultations had significantly more
concomitant heroin use (43% versus 60%). This result is not consistent with the
results of McLellan and colleagues (1993) which demonstrated that none of the
patients with methadone dispensing alone achieved a 16 consecutive weeks of
negative urines, 28% of those with methadone + standard counseling achieved 16
consecutive weeks of negative urines, and those with methadone + enhanced
counseling achieved 55%. On the other hand, recent studies with randomized
designs have failed to show consistently that the provision of additional services,
achieve better outcomes than MMT without councselling (Mattick et al., 1998; Kraft et
al., 1997). In the present study, one possible explanation could be that physicians
schedule more consultations for the more “problematic patients”, whereas the “well
functioning patients” receive less consultations, according to clinical evidence.
Evidence for this interpretation was additionally found in a significantly higher
proportion of patients with concomitant cocaine use as well as intravenous drug use
in the ‘high rate’ consultation group. Taken together the results indicate, that
improved treatment outcome is associated with a higher rate of offered consultations.
Compared to an earlier survey conducted by von Bardeleben and colleagues (1993),
the number of offered consultations by physicians in a six-month period has
decreased from a mean of 9.0  7 to 7.4  5, and proportionally the number of
attended consultations by the patients decreased from 8.4  6 to 6.3  5 in the last
10-year period. Overall, scheduled and attended consultations showed considerable
variations from one program to another, probably due to different fulltime equivalents
(FTE) between specialized clinics and general practice. The number of scheduled
and attended consultations remained stable over time, indicating consistency of
treatment services at one-year follow-up. In summary these findings in 1993 and
2001 indicate, that patients’ behave in attending approximately one consultation less
than scheduled by their doctors.
Treatment cooperation and treatment outcome: In order to get a more precise
impression of the relation between the attendance of consultations and treatment
outcome, we compared patients with a “good cooperation” (GC) (compliant patients)
and those with a “unsatisfactory cooperation” (UC) (non-compliant patients) and
found evidence-based results. We hypothesized, that patients with a worse social
functioning, multiple substance use and a higher proportion of dual diagnosis would
show a unsatisfactory treatment  cooperation. Our results showed, that patient with a
“good cooperation” were significantly more often employed (better social functioning),
had less multiple substance use at entry in MMT, and a lower rate of co-morbidity,
significantly less concomitant cocaine use and more take-home privileges. These
results provide further support of the relation between patients’ co-morbidity,
compliance, and treatment outcomes which has been demonstrated in previous
studies (Gold & Slaby, 1991; Cacciola et al., 2001). Interestingly, a significantly
higher proportion of women was found in the non-compliant group. One possible
explanation could be, that women are more involved in parenthood obligations, have
more often a relation to an addicted  spouse, and as a consequence have less time
to attend the consultations compared to men (Hser et al., 2003).
Treatment failures versus in-treatment patients: Evidence was found, that treatment
failures had significantly lower methadone doses, less prescribed co-medication, less
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take-home privileges and attended less consultations than patients remaining in
MMT. Thus, as discussed in the previous section, in-treatment variables (methadone
dosage policy, take-home medication, attendance of consultations) seem to have a
higher impact on retention in treatment than patient variables. This was postulated by
Ball & Ross in their large-scale study (1991). These results were emphasized by the
analysis of potential predictors of treatment failure in this cohort study. Only two in-
treatment variables were identified as predictors for treatment failure: continuous
intravenous drug use in MMT and concomitant cocaine use.
In conclusion, patients in this large-scale study with a one-year follow-up showed
improvements on most of the key outcome variables in a MMT. Their use of heroin
was halved, and substantial reductions were found for cocaine. There were also
improvements in physical health status at follow-up. The present study showed
substantial reductions in a range of problem behaviors among unselected samples of
opioid dependent patients which are sustained to one-year follow-up. An association
between amount of consultations and improved outcomes could be demonstrated for
retention in treatment.
4.2 Methadone Maintenance in General Practice versus in Specialized Clinics
The second part of the discussion focus on the results comparing treatment
outcomes in general practice (n = 200) versus in specialist clinic settings (n = 460).
We hypothesized that patients treated in general practice would have better or equal
treatment outcomes compared to patients treated in specialized clinics with GPs’
treating more stable patients. Thus, we aimed to demonstrate the clinical significance
and the stability of treatment outcome in the two treatment modalities over time. A
second research question focussed on the relation between the number of attended
consultations and treatment outcome in MMT in primary care versus in specialized
clinics. We hypothesized, that patients in general practice would proportionally attend
more scheduled consultations than those treated in specialized clinics.
Patients treated in both the general practices and the specialized clinics settings
showed improvements on most of the main outcome variables. We compared to
populations with similar baseline variables: gender, marital status, nationality, age at
begin of heroin, cocaine use, and age at begin of MMT. However, the two
populations differed significantly in age (33.8 yrs versus 35.8 yrs). Furthermore
patients treated in GP had a lower proportion of patients with multiple substance use
at MMT entry and started at an older age with alcohol use, indicating a lower rate of
co-morbidity. Prevalence rates of HIV and HAV, HBV and HCV differed between
groups, again showing patients in general practice with a better health status.
The main findings for the one-year retention in treatment were the following: The
overall retention rate was 73.6%. The one-year retention rate for patients in general
practice was 76%, and for patients in clinics 72%, thus did not differ significantly. As
we hypothesized, the mean survival time for GP patients was significantly longer,
than for clinic patients (16.9 years vs. 13.5 years). Our results are consistent with
those in the Swiss methadone case register analysis of Falcato et al. (2002) in
Zurich, including a total of 524 in general practice versus 550 patients in specialized
institutions over five years. They found a significantly longer retention time for
patients treated in general practice (Kaplan-Meier; P < 0.001). Consistent with our
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results was a methadone case register analysis of Petitjean & Schaller in Geneva,
including a total of 1034 patients (454 in general practice versus 580 patients in
specialized institutions) (Petitjean & Schaller, 2002b). They found a significant longer
survival time in treatment for patients treated by GPs. The results in our study are not
consistent with the findings in a RCT of Fiellin et al. (2001) and the observational
study of Gossop et al. (1999). They found no differences in retention between the GP
and the clinic group. One explanation could be, that Fiellin included only highly
selected stable patients in his study without dependencies on other substances,
without psychiatric co-morbidity, and without concomitant drug use.
Reduction of heroin use: Evidence was obtained that concomitant heroin use
decreased in both treatment settings over time for patients retained in the study
(completer analysis). Concomitant cocaine use remained stable over time. As we
hypothesized, the proportion of patients with self-reported Illicit heroin and cocaine
use in the past 30 days was significantly lower in patients treated by GPs (heroin:
42% versus 64%; cocaine: 19% versus 42%) compared to patients treated in clinics.
Patients in general practice had also a significantly smaller proportion of patients with
multiple substance use (75%) compared to those treated in clinics (93%), and a
significantly lower proportion of patients with intravenous drug use in the past six
months prior interview (34% versus 49%). Alcohol use outcomes were poor for both
groups with little change in frequency of drinking. Poor drinking outcomes have been
reported elsewhere (Gossop et al., 1999; 2003; Hubbard et al., 1989). Concomitant
alcohol use is a problem for both settings of MMT. Cannabis use remained
unchanged too and the use of non prescribed benzodiazepines is high in this
population (Ladewig & Simoni, 1996).
An association between the amount of consultations and improved outcomes has
been reported (Etheridge et al., 1995; Fiorentine et al., 1996; McLellan et al., 1988,
1993). To our knowledge, this is the first study demonstrating, that the provision of
more consultations is more effective for MMT outcomes, both in general practice and
in specialist clinic settings. Consistent with previous studies, the provision of services
in addition to the administration of methadone has been shown to lead to improved
outcomes (Ball & Ross, 1991; McLellan et al., 1993). Individual counseling sessions
are the base of all treatment modalities in MMT, and they constitute one of the most
frequent forms of therapeutic contact within methadone programs. Simpson et al.
(1982) also reported that program participation as measured by session attendance
was related both to improved drug use outcomes and to higher patient satisfaction
ratings.
For patients treated in general practice in our study an association between session
attendance and improved drug use outcomes was found, but on a non significant
level. GP patients with a high rate of consultations had less concomitant heroin use
compared to GP patients a low rate of consultations (29.4% versus 41.8%). For
patients treated in clinics this association was not found. Clinic patients with a high
rate of consultations had significantly more concomitant heroin use compared to
clinic patients with a low rate of consultations (61.5% versus 35.6%). Indicating, that
physicians in the clinics schedule more consultations for the more “problematic
patients”, thus providing individually targeted interventions.
Somewhat surprising was the fact, that the equal proportion of non-compliant patients
in both the GPs and the specialist clinic settings (25% versus 23%). We expected
that GPs would have a smaller proportion of patients with an unsatisfactory
cooperation (UC) than the clinics. One explanation could be the fact, that most GPs
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provide MMT to opioid-dependent patients since the late seventies in the area of
Basel, and as a consequence have a lot of experience, allowing them to treat and to
cope with difficult patients.
The finding that patients do attend approximately one consultation less than
scheduled by their physicians in private practices as well as in specialized clinics
indicates, that the cooperation between the patients and their physician is as good in
both settings. Patients in primary care attended an average of 5.14 out of 6.19
scheduled consultations, patients in clinics attended an average of 6.80 out of 7.86
scheduled consultations in a six-month period. As expected, the patients treated in
general practice had significantly less scheduled, respectively attended consultations
than those in specialized clinics. This could be explained by a higher physician-
patient ratio in specialized clinics, thus physicians having more time for their patients
compared to general practices.
One limitation of the study is, that we have to be aware, that the amount of
consultations/ counselling per se may not be the active ingredient of treatment. It may
be more important to provide specifically targeted interventions (Avants et al., 1998).
We do not know the ingredients of the assessed number of consultations in this
cohort study.
Methadone doses prescribed by GPs’ were lower, but differed not on a statistically
significant level at the first interview. Daily methadone doses were in a good
therapeutic range (69.3  44.7 mg versus 76.7   48.4 mg) (Payte et al., 1993).
Doses prescribed by clinics increased significantly over time and this result is
consistent with the results of a multi-site observational study in Amsterdam of
Langendam et al. (1998). Surprisingly, the amount of take-home medication did not
differ between groups as well as the proportion of patients with a comedication. This
result is surprising, because the three specialized clinics were supposed to treat
more “problematic patients” with more co-morbidities (somatic, psychiatric, social)
than the GPs. Therefor we would expect less patients with take-home medication and
more patients with a comedication. On the other hand, this result could reflect, that
GPs with a long experience in MMT treat a substantial subgroup of patients with co-
morbidities. These results are consistent with the results about cooperation.
Multi-site, prospective studies of this kind have the merit of representing patients and
services in the real world, and have high external validity and allow a generalization
of the findings (Simpson et al., 1999). This prospective observational study has some
limitations which needs to be addressed. First the absence of random assignment
and a non-treated control group (Fletcher et al., 1997). Due to ethical purposes,
opioid dependent patients are nowadays not allocated anymore to “waiting lists” or
treated with a placebo. The lack of random assignment requires great caution in
making any inferences from the outcomes achieved by patients in the two treatment
settings. However, although the patients in this study were not randomly allocated to
the different treatment modalities, the patients receiving methadone treatment from
GPs or from clinics were similar in their demographics, and in the type and severity of
their substance use behaviours and other presenting problems at intake. There was
no systematic selection process by which patients were allocated to either physicians
in general practice or to clinics. The main problem drug in both treatment groups was
heroin and multiple substance use was common.
Greater caution is needed with regard to interpreting the findings of the GP sample in
our study. This group of GPs may not be representative for all GPs, because they
represent approximately 20 percent of all GPs in the City of Basel. But they are
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representative for a typical setting of a general practice, having a major part of other
non-substance use patients and a mean of 3 patients with substance use disorders in
each private practice. Nevertheless, in an recent representative Swiss survey of
private practitioners (n = 129), 80 percent of the private practitioners’ noted, that they
would encourage a physician colleague to take some methadone maintained patients
in his practice, and only 10 percent would not recommend their colleagues to take a
patient in a MMT, due to “personal problematic experiences” (Hermann, 2001). This
result indicates a high acceptance within physicians for addicted patients.
The reliability of self-reports of the use of drugs over a defined time period is open to
question. While underreporting of concomitant heroin use is common (Harrison et al.,
1995), there is some evidence according to Farabee & Fredlund (1996), that people
who have participated in a replacement therapy with methadone may be more likely
to report that they have used drugs than are those who have not been in any
treatment. To control concomitant drug use or alcohol use, physicians in both settings
collect urine specimens or do a breath test with their patients if appropriate. These
urinalyses are done on a individually targeted way. That is, some doctors control
concomitant drug use weekly, others monthly. These urinalyses results were not
asked in the questionnaire, because earlier surveys provided 80% of missing values
in this section. The fact that some patients did not tell the truth by underreporting
concomitant drug use or HIV risk behaviour to their doctors could be a limitation of
the present study.
A further limitation of the study could be the lack of information of the contents and
the length of the consultations and counseling. As Zanis states, “regardless the
source, recording treatment service data on the individual patient level is a complex
task that involves the assessment of multiple factors including the type, frequency,
quality and quantity of treatment services” (1997, p. 31). Results of their study
showed that measures of treatment service delivery can vary, based on who provides
the information (e.g. patient or physician/ treatment staff) and what different
procedures are used for data collection (self-report versus record abstraction).
Nevertheless, there was a good correspondence between the estimates of the
physicians/ treatment staff and the patients. As Simpson states, “although much
remains unknown about the “black box” of methadone maintenance treatment, and
what occurs during the treatment process, the measure of the frequency of offered
and attended consultations to the patient provides some insight into this area”
(Simpson & Sells, 1982, p. 27).
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5. Conclusions
In conclusion, this study yielded positive results and improvements for patients in
MMT in general practice and in specialized clinics in terms of attended consultations
treatment cooperation, concomitant drug use and retention time in treatment. There
were some differences between treatment in general practice and in clinics. Results
show substantial reductions in concomitant heroin use, among samples of opiate-
dependent patients treated in GP and in clinic settings, which are sustained to one-
year follow-up. Our results support the effectiveness of methadone maintenance
provided by primary care physicians’ offices and favour a stronger participation of
private practitioners in MMT. Providing better professional support and financial
compensation may enhance their engagement.
The results of this study provide further support for the feasibility and effectiveness of
methadone treatment provided within a primary care setting, and show that treatment
outcomes for such patients can be as satisfactory as for patients in specialist drug
clinics. These results support the findings in studies from Britain and Australia, which
reported on the feasibility of prescribing methadone within primary health care
settings (Byrne et al., 2000; Gruer et al., 1997; Weinrich & Stuart, 2000). Furthermore
these results demonstrate that GPs’ treat a substantial subgroup of problematic
patients in their practices (25%) , showing a great experience in the field of addiction,
due to a long duration of patient-doctor contacts over years, in some cases for nearly
20 years.
Despite the positive findings of this study, our results also raise questions about
certain GP and clinics prescribing practices. A subgroup of patients have methadone
take-home privileges despite regular concomitant heroin and cocaine use, continuing
risk behavior, and attending less consultations. Furthermore, targeted interventions
should be developed and provided for different subgroups of patients (e.g. prevention
and treatment of blood-borne infections, especially for women; CBT for cocaine and
alcohol dependent patients). Additionally more employment and educational
possibilities should be developed and implemented for MM patients. Resolving such
difficulties with “problematic patients” represents a major challenge for future
provision of methadone treatment in general practice and in specialist clinic settings.
Finally knowledge and training to provide medical maintenance should be provided
by the health authorities and the specialist clinic settings to the physicians.
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